

DESCRIPTION

HETEROCYCLIC DERIVATIVES AND USE THEREOF

FIELD OF THE INVENTION

The present invention relates to novel heterocyclic compounds, uses thereof for the prevention or treatment of diseases associated with the activation of STAT proteins, particularly, STAT3 protein and pharmaceutical compositions comprising same.

BACKGROUND OF THE INVENTION

Signal transducer and activator of transcription (STAT) proteins are transcription factors which transduce signals from various extracellular cytokines and growth factors to a nucleus. Seven (7) subtypes of STAT proteins (i.e., STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6) are currently known, and generally they consist of about 750 - 850 amino acids. In addition, each subtype of STAT proteins contains several conserved domains which play an important role in exhibiting the function of STAT proteins. Specifically, five (5) domains from N-terminus to C-terminus of STAT proteins have been reported including coiled-coiled domain, DNA binding domain, linker domain, SH2 domain and transactivation domain (TAD)). Further, X-ray crystalline structures of STAT1, STAT3, STAT4 and STAT5 have been reported since 1998 (Becker S *et al.*, *Nature*, 1998, 394; Vinkemeier U *et al.*, *Science*, 1998, 279; Chen X *et al.*, *Cell*, 1998, 93; D. Neculai *et al.*, *J. Biol. Chem.*, 2005, 280). In general, receptors to which cytokines and growth factors bind are categorized into Class I and Class II. IL-2, IL-3, IL-5, IL-6, IL-12, G-CSF, GM-CSF, LIF, thrombopoietin, etc., bind to Class I receptors, while INF- α , INF- γ , IL-10, etc., bind to Class II receptors (Schindler C *et al.*, *Annu. Rev. Biochem.*, 1995, 64; Novick D *et al.*, *Cell*, 1994, 77; Ho AS *et al.*, *Proc. Natl. Acad. Sci.*, 1993, 90). Among them, the cytokine receptors involved in the activation of STAT proteins can be classified depending on their structural forms of extracellular domains into a gp-130 family, an IL-2 family, a growth factor family, an interferon family and a receptor tyrosine kinase family. Interleukin-6 family cytokines are representative multifunctional cytokines which mediate various physiological activities. When interleukin-6 cytokine binds to IL-6 receptor which is present on the cell membrane surface, it attracts gp-130 receptor to form an IL-6-gp-130 receptor complex. At the same time, JAK kinases (JAK1, JAK2, JAK3 and Tyk2) in the cytoplasm are recruited to a cytoplasmic region of gp130 to be phosphorylated and activated. Subsequently, latent cytoplasmic STAT proteins are attracted to a receptor, phosphorylated by JAK kinases and activated.

Tyrosine-705 adjacent to the SH2 domain located in the C-terminus of STAT proteins is phosphorylated, and the activated tyrosine-705 of each STAT protein monomer binds to the SH2 domain of another monomer in a reciprocal manner, thereby forming a homo- or heterodimer. The dimers are translocated into a nucleus and bind to a specific DNA binding promoter to promote the transcription. Through its transcription process, various proteins (Myc, Cyclin D1/D2, Bcl-xL, Mcl, survivin, VEGF, HIF-1, immune suppressors, etc.) associated with cell proliferation, survival, angiogenesis and immune evasion are produced (Stark et al., *Annu. Rev. Biochem.*, 1997, 67; Levy et al., *Nat. Rev. Mol. Cell Biol.*, 2002, 3).

In particular, STAT3 protein is known to play a crucial role in the acute inflammatory response and the signal transduction pathway of IL-6 and EGF (Akira et al., *Cell*, 1994, 76; Zhong et al., *Science*, 1994, 264). According to the recent clinical report, STAT3 protein is constantly activated in patients with solid cancers occurring in prostate, stomach, breast, lung, pancreas, kidney, uterine, ovary, head and neck, etc., and also in patients with blood cancer such as acute and chronic leukemia, multiple myeloma, etc. Further, it has been reported that the survival rate of a patient group with activated STAT3 is remarkably lower than that of a patient group with inactivated STAT3 (Masuda et al., *Cancer Res.*, 2002, 62; Benekli et al., *Blood*, 2002, 99; Yuichi et al., *Int. J. Oncology*, 2007, 30). Meanwhile, STAT3 was identified to be an essential factor for the growth and maintenance of murine embryonic stem cells in a study employing a STAT3 knockout mouse model. Also, a study with a tissue-specific STAT3-deficient mouse model reveals that STAT3 plays an important role in cell growth, apoptosis, and cell motility in a tissue-specific manner (Akira et al., *Oncogene* 2000, 19). Moreover, since apoptosis induced by anti-sensing STAT3 was observed in various cancer cell lines, STAT3 is considered as a promising new anticancer target. STAT3 is also considered as a potential target in the treatment of patients with diabetes, immune-related diseases, hepatitis C, macular degeneration, human papillomavirus infection, non-Hodgkin's lymphoma, tuberculosis, etc. Meanwhile, newly identified Th17 cells have been reported through a number of recent articles to be associated with various autoimmune diseases (Jacek Tabarkiewicz et al., *Arch. Immunol. Ther. Exp.*, 2015, 11). Based on these reports, a control of the differentiation and function of Th17 cells is considered as a good target in the treatment of related diseases. In particular, since STAT3-dependent IL-6 and IL-23 signal transductions are known as important factors in the differentiation of Th17 cells (Xuexian O. Yang et al., *J. Biol. Chem.*, 2007, 282; Harris T J et al., *J. Immunol.*, 2007, 179), an inhibition of the function of STAT3 is expected to be effective in the treatment of diseases associated with Th17 cells such as systemic lupus erythematosus, uveitis, rheumatoid arthritis, autoimmune thyroid disease, inflammatory bowel disease, psoriasis and psoriatic arthritis (Jacek Tabarkiewicz et al., *Arch. Immunol. Ther. Exp.*, 2015, 11).

Recently, IL-6 and IL-23 antibodies are under clinical studies on the treatment of arthritis and psoriasis associated with Th17 cells and exhibit a clinical efficacy (Nishimoto

N. et al., *Arthritis Rheum.*, 2004, 50; Gerald G. et al., *N. Engl. J. Med.*, 2007, 356). This also confirms that the inhibition of STAT3 signal transduction is an effective therapeutic method for such diseases.

In contrast, while having intracellular response pathways of identical cytokines and growth factors to those of STAT3, STAT1 increases inflammation and congenital and acquired immunities to inhibit the proliferation of cancer cells or cause pro-apoptotic responses, unlike STAT3 (Valeria Poli *et al.*, *Review, Landes Bioscience*, 2009).

In order to develop STAT3 inhibitors, the following methods can be considered: i) inhibition of the phosphorylation of STAT3 protein by IL-6/gp-130/JAK kinase, ii) inhibition of the dimerization of activated STAT3 proteins, and iii) inhibition of the binding of STAT3 dimer to nuclear DNA. Small molecular STAT3 inhibitors are currently under development. Specifically, OPB-31121 and OPB-51602 are under clinical studies on patients with solid cancers or blood cancers by Otsuka Pharmaceutical Co., Ltd. Further, S3I-201 (Siddiquee *et al.*, *Proc. Natl. Acad. Sci.*, 2007, 104), S3I-M2001 (Siddiquee *et al.*, *Chem. Biol.*, 2007, 2), LLL-12 (Lin *et al.*, *Neoplasia*, 2010, 12), Stattic (Schust *et al.*, *Chem. Biol.* 2006, 13), STA-21 (Song *et al.*, *Proc. Natl. Acad. Sci.*, 2005, 102), SF-1-066 (Zhang *et al.*, *Biochem. Pharm.*, 2010, 79) and STX-0119 (Matsuno *et al.*, *ACS Med. Chem. Lett.*, 2010, 1), etc. have been reported to be effective in a cancer cell growth inhibition experiment and in animal model (in vivo Xenograft model). Furthermore, although peptide compounds mimicking the sequence of amino acid of pY-705 (STAT3) adjacent to the binding site to SH2 domain or the amino acid sequence of gp-130 receptor in which JAK kinases bind were studied (Coleman *et al.*, *J. Med. Chem.*, 2005, 48), the development of the peptide compounds has not been successful due to the problems such as solubility and membrane permeability.


SUMMARY OF THE INVENTION

Accordingly, it is an object of the present invention to provide novel heterocyclic derivatives for the inhibition of the activation of STAT3 protein.

It is another object of the present invention to provide uses of the heterocyclic derivatives for the prevention or treatment of diseases associated with the activation of STAT3 protein.


The invention is defined in the independent claims. Further embodiments of the invention are defined in the dependent claims.

In accordance with one aspect of the present invention, there is provided a compound selected from the group consisting of a heterocyclic derivative represented by formula (I), and a pharmaceutically acceptable salt and a stereoisomer thereof:



wherein

X_1 and X_2 are each independently $-C(-R_x)(-R_x'')$ -, $-C(-R_x')(-R_x'')$ -, $-C(-R_x'')(-R_x'')$ -, $-C(=O)$ -, $-N(R_x)$ -, $-N(-R_x')$ -, $-N(-R_x'')$ -, or $-O$ -;



X_s is $=O$ or $=NH$;

R_s is C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkylcarbonyl- C_{1-6} alkyl, C_{2-7} alkenyl, amino, or amino C_{1-6} alkyl;

R_x' is halo C_{1-6} alkyl, C_{1-4} alkoxycarbonyl, cyano, nitro, azido, amino, or a 3- to 6-membered heterocyclyl unsubstituted or substituted with R_x'' ;

R_x'' is each independently hydrogen, halogen, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, carbamoyl C_{1-6} alkyl, C_{1-6} alkylamino- C_{1-6} alkyl, or di C_{1-6} alkylamino- C_{1-6} alkyl;

one of Y and Z is $-S-$ or $-NH-$, and the other is $-CH=$ or $-N=$;

L_x is a saturated or unsaturated C_{1-4} hydrocarbon chain not containing or containing 1 to 3 heterogroups selected from the group consisting of $-O-$, $-NH-$, $-N=$, $-S-$, $-S(=O)-$ and $-S(=O)_2-$ in the chain, and unsubstituted or substituted with at least one R_x'' moiety;

A and B are each independently a monocyclic- or bicyclic-saturated or unsaturated C_{3-10} carbocycle or 5- to 12-membered heterocycle;

R_c is $=O$, $=NH$, $=N(-C_{1-6}alkyl)$, or $=N(-OH)$;

R_N is hydrogen or $C_{1-6}alkyl$;

L_B is $-[C(-R_L)(-R_L')]_m-$, $-[C(-R_L)(-R_L')]_n-O-$, $-O-$, $-NH-$, $-N(C_{1-6}alkyl)-$, $-S(=O)_2-$, $-C(=O)-$, or $-C(=CH_2)-$, wherein m is an integer of 0 to 3, n is an integer of 1 to 3, R_L and R_L' are each independently hydrogen, hydroxy, halogen or $C_{1-6}alkyl$, or R_L and R_L' are linked together to form $C_{1-6}alkylene$;

R_A is hydrogen, halogen, cyano, $C_{1-6}alkyl$, halo $C_{1-6}alkyl$, cyano $C_{1-6}alkyl$, $C_{1-6}alkylcarbonyl$, $C_{1-6}alkoxy$, halo $C_{1-6}alkoxy$, cyano $C_{1-6}alkoxy$, $C_{1-6}alkylamino$, di $C_{1-6}alkylamino$, $C_{1-6}alkylthio$, $C_{1-6}alkylaminocarbonyl$, di $C_{1-6}alkylaminocarbonyl$, $C_{2-8}alkynyl$, $C_{1-6}alkoxycarbonylamino-C_{1-6}alkoxy$, amino $C_{1-6}alkoxy$, or 3- to 6-membered heterocyclyl;

R_B is hydrogen, halogen, hydroxy, cyano, nitro, amino, oxo, aminosulfonyl, sulfonylamido, $C_{1-6}alkylamino$, $C_{1-6}alkyl$, halo $C_{1-6}alkyl$, cyano $C_{1-6}alkyl$, $C_{1-6}alkoxy$, halo $C_{1-6}alkoxy$, cyano $C_{1-6}alkoxy$, $C_{3-8}cycloalkyloxy$, $C_{2-8}alkenyl$, $C_{2-8}alkenyloxy$, $C_{2-8}alkynyl$, $C_{2-8}alkynyloxy$, $C_{1-6}alkylamino-C_{1-6}alkoxy$, di $C_{1-6}alkylamino-C_{1-6}alkoxy$, $C_{1-6}alkoxy-carbonyl$, carbamoyl, carbamoyl- $C_{1-6}alkoxy$, $C_{1-6}alkylthio$, $C_{1-6}alkylsulfinyl$, $C_{1-6}alkylsulfonyl$, 5- to 10-membered heterocyclyl, 5- to 10-membered heterocyclyl- $C_{1-6}alkyl$, 5- to 10-membered heterocyclyl- $C_{1-6}alkoxy$, or 5- to 10-membered heterocyclyl-oxy;

p is an integer of 0 to 4, and, when p is 2 or higher, R_A moieties are the same as or

different from each other;

q is an integer of 0 to 4, and, when q is 2 or higher, R_B moieties are the same as or different from each other; and

each of said heterocycle and heterocyclyl moieties independently contains at least one heterogroup selected from the group consisting of -O-, -NH-, -N=, -S-, -S(=O)- and -S(=O)₂-.

In accordance with another aspect of the present invention, there is provided a use of a compound selected from the group consisting of a heterocyclic derivative represented by formula (I) above, and a pharmaceutically acceptable salt and a stereoisomer thereof for the manufacture of a medicament for preventing or treating diseases associated with the activation of STAT3 protein.

In accordance with a further aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating diseases associated with the activation of STAT3 protein, comprising a compound selected from the group consisting of a heterocyclic derivative represented by formula (I) above, and a pharmaceutically acceptable salt and a stereoisomer thereof as active ingredients.

In accordance with a still further aspect of the present invention, there is provided a method for preventing or treating diseases associated with the activation of STAT3 protein in a mammal, which comprises administering a compound selected from the group consisting of a heterocyclic derivative represented by formula (I) above, and a pharmaceutically acceptable salt and a stereoisomer thereof to the mammal.

The heterocyclic derivative represented by formula (I) above, or a pharmaceutically acceptable salt or a stereoisomer thereof has an excellent inhibitory effect on the activation of STAT3 protein, and thus it can be used for the prevention or treatment of diseases associated with the activation of STAT3 protein.

DETAILED DESCRIPTION OF THE INVENTION

The present invention will be further described in detail herein below.

In the specification of the present invention, the term "halogen" refers to fluoro, chloro, bromo or iodo, unless specified otherwise.

The term "alkyl" refers to a linear or branched hydrocarbon moiety, unless specified otherwise.

The terms "haloalkyl", "haloalkoxy", "halophenyl", etc., respectively refer to alkyl, alkoxy, and phenyl substituted with at least one halogen.

The term "carbocycle" refers to an aromatic or non-aromatic hydrocarbon ring, which may be saturated or unsaturated, and a monocyclic or polycyclic radical. The term

“carbocyclyl” refers to a radical of “carbocycle”, and is used as a term inclusive of “cycloalkyl” and “aryl”. The term “cycloalkyl” refers to a saturated hydrocarbon radical, which may be monocyclic or polycyclic. The term “aryl” refers to an aromatic hydrocarbon ring, which may be monocyclic or polycyclic.

The terms “carbocycle”, “carbocyclyl”, “cycloalkyl” and “aryl” may refer to, for example, a monocycle or polycycle having 3 to 20 carbon atoms, and will be indicated as “C₃₋₂₀ carbocycle”, “C₃₋₂₀ carbocyclyl”, “C₃₋₂₀ cycloalkyl”, and “C₃₋₂₀ aryl”, respectively.

The term “heterocycle” refers to an aromatic or non-aromatic ring having at least one heteroatom, which may be saturated or unsaturated, and a monocycle or polycycle.


The term “heterocyclyl” refers to a radical of “heterocycle”, which is used as a term inclusive of “heterocycloalkyl” and “heteroaryl”. The term “heterocycloalkyl” refers to a saturated ring radical having at least one heteroatom, which may be monocyclic or polycyclic. The term “heteroaryl” refers to an aromatic ring radical having at least one heteroatom, which may be monocyclic or polycyclic.

The term “heteroatom” may be selected from N, O and S.

The terms “heterocycle”, “heterocyclyl”, “heterocycloalkyl” and “heteroaryl” may refer to, for example, a mono- or polycycle having 3 to 20 heteroatoms and/or carbon atoms, and will be indicated as “3- to 20-membered heterocycle”, “3- to 20-membered heterocyclyl”, “3- to 20-membered heterocycloalkyl”, and “3- to 20-membered heteroaryl”.


The terms “chain” refers to a saturated or unsaturated C₂₋₁₀ hydrocarbon chain not containing any heteroatoms in the chain, for example, ethylene, propylene, butylene and -CH₂-CH=CH-; or a saturated or unsaturated C₂₋₁₀ hydrocarbon chain containing at least one heterogroup selected from the group consisting of -O-, -NH-, -N=, -S-, -S(=O)- and -S(=O)₂- in the chain, for example, -CH₂-O-CH₂-, -CH₂-O-CH₂-O-CH₂-, -CH₂-CH=CH-NH- and -CH₂-CH₂-S(=O)₂-CH₂-O-, unless specified otherwise. The chain may be substituted with at least one selected from the group consisting of halogen, C₁₋₆alkyl and C₁₋₆alkoxy.

In accordance with one aspect of the present invention, there is provided a compound selected from the group consisting of a heterocyclic derivative represented by formula (I), and a pharmaceutically acceptable salt and a stereoisomer thereof:



wherein

X₁ and X₂ are each independently -C(-Rx)(-Rx'')-, -C(-Rx')(-Rx'')-, -C(-Rx'')(-Rx'')-, -C(=O)-, -N(Rx)-, -N(-Rx')-, -N(-Rx'')-, or -O-;



Rx is

Xs is =O or =NH;

Rs is C₁₋₆alkyl, haloC₁₋₆alkyl, C₁₋₆alkoxy-C₁₋₆alkyl, C₁₋₆alkylcarbonyl-C₁₋₆alkyl, C₂₋₇alkenyl, amino, or aminoC₁₋₆alkyl;

5 Rx' is haloC₁₋₆alkyl, C₁₋₄alkoxycarbonyl, cyano, nitro, azido, amino, or a 3- to 6-membered heterocyclyl unsubstituted or substituted with Rx";

Rx" is each independently hydrogen, halogen, nitro, amino, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, carbamoylC₁₋₆alkyl, C₁₋₆alkylamino-C₁₋₆alkyl, or diC₁₋₆alkylamino-C₁₋₆alkyl;

10 one of Y and Z is -S- or -NH-, and the other is -CH= or -N=;

Lx is a saturated or unsaturated C₁₋₄ hydrocarbon chain not containing or containing 1 to 3 heterogroups selected from the group consisting of -O-, -NH-, -N=, -S-, -S(=O)- and -S(=O)₂- in the chain, and unsubstituted or substituted with at least one Rx" moiety;

15 A and B are each independently a monocyclic- or bicyclic-saturated or unsaturated C₃₋₁₀carbocycle or 5- to 12-membered heterocycle;

Rc is =O, =NH, =N(-C₁₋₆alkyl), or =N(-OH);

R_N is hydrogen or C₁₋₆alkyl;

20 L_B is -[C(-R_L)(-R_L')]_m-, -[C(-R_L)(-R_L')]_n-O-, -O-, -NH-, -N(C₁₋₆alkyl)-, -S(=O)₂-, -C(=O)-, or -C(=CH₂)-, wherein m is an integer of 0 to 3, n is an integer of 1 to 3, R_L and R_L' are each independently hydrogen, hydroxy, halogen or C₁₋₆alkyl, or R_L and R_L' are linked together to form C₁₋₆alkylene;

25 R_A is hydrogen, halogen, cyano, C₁₋₆alkyl, haloC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkylcarbonyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, cyanoC₁₋₆alkoxy, C₁₋₆alkylamino, diC₁₋₆alkylamino, C₁₋₆alkylthio, C₁₋₆alkylaminocarbonyl, diC₁₋₆alkylaminocarbonyl, C₂₋₈alkynyl, C₁₋₆alkoxycarbonylamino-C₁₋₆alkoxy, aminoC₁₋₆alkoxy, or 3- to 6-membered heterocyclyl;

30 R_B is hydrogen, halogen, hydroxy, cyano, nitro, amino, oxo, aminosulfonyl, sulfonylamido, C₁₋₆alkylamino, C₁₋₆alkyl, haloC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, cyanoC₁₋₆alkoxy, C₃₋₈cycloalkyloxy, C₂₋₈alkenyl, C₂₋₈alkenyloxy, C₂₋₈alkynyl, C₂₋₈alkynyloxy, C₁₋₆alkylamino-C₁₋₆alkoxy, diC₁₋₆alkylamino-C₁₋₆alkoxy, C₁₋₆alkoxy-carbonyl, carbamoyl, carbamoyl-C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyl, 5- to 10-membered heterocyclyl, 5- to 10-membered heterocyclyl-C₁₋₆alkyl, 5- to 10-membered heterocyclyl-C₁₋₆alkoxy, or 5- to 10-membered heterocyclyl-oxy;

35 p is an integer of 0 to 4, and, when p is 2 or higher, R_A moieties are the same as or different from each other;


q is an integer of 0 to 4, and, when q is 2 or higher, R_B moieties are the same as or different from each other; and

each of said heterocycle and heterocyclyl moieties independently contains at least one heterogroup selected from the group consisting of -O-, -NH-, -N=, -S-, -S(=O)- and -S(=O)₂-.

- 5 In a preferred embodiment of the compound of formula (I),
one of Y and Z is -S- or -NH-, and the other is -CH=;

Lx is a saturated C₁₋₃ hydrocarbon chain not containing or containing at least one heteroatom selected from the group consisting of O, N and S in the chain, and unsubstituted or substituted with at least one substituent selected from the group consisting
10 of halogen, C₁₋₆alkyl and C₁₋₆alkoxy;

one of X₁ and X₂ is -C(-Rx)(-Rx'')-, -C(-Rx')(-Rx'')-, -C(=O)-, -N(Rx)- or -N(-Rx')-, and the other is -C(-Rx'')(-Rx'')-, -N(-Rx'')- or -O-;



Rx is

Xs is =O or =NH;

- 15 Rs is C₁₋₆alkyl or haloC₁₋₆alkyl;

Rx' is haloC₁₋₆alkyl, cyano, nitro, amino, azido, or a 5- to 6-membered heterocyclyl containing at least one heteroatom selected from the group consisting of N, S and O and unsubstituted or substituted with oxo;

Rx'' is hydrogen, halogen, C₁₋₆alkyl, or C₁₋₄alkoxycarbonyl; and

- 20 Rc, R_N, A, B, L_B, R_A, R_B, p and q are the same as defined above in formula (I).

In a preferred embodiment of the compound of formula (I),

Y is -CH=;

Z is -S-;


- 25 Rc is =O;

R_N is hydrogen;

Lx is a saturated C₁₋₃ hydrocarbon chain not containing or containing oxygen atom in the chain, and unsubstituted or substituted with at least one substituent selected from the group consisting of halogen, C₁₋₆alkyl and C₁₋₆alkoxy;

- 30 X₁ is -C(-Rx)(-Rx'')-, -C(-Rx')(-Rx'')-, or -N(Rx)-;

X₂ is -C(-Rx'')(-Rx'')-, -C(=O)-, -N(-Rx'')-, or -O-;



Rx is

Xs is =O or =NH;

- 35 Rx' is haloC₁₋₆alkyl, cyano, nitro, amino, azido, or a 5- to 6-membered heterocyclyl containing 1 to 2 heteroatoms selected from N and O and unsubstituted or substituted with oxo;

Rx" is hydrogen, halogen, C₁₋₆alkyl, or C₁₋₄alkoxycarbonyl; and
A, B, L_B, R_A, R_B, p and q are the same as defined above in formula (I).

In a preferred embodiment of the compound of formula (I),

Y is -CH=;

Z is -S-;


R_c is =O;

R_N is hydrogen;

L_x is a saturated C₁₋₃ hydrocarbon chain not containing or containing oxygen atom
in the chain, and unsubstituted or substituted with at least one substituent selected from the
group consisting of halogen, C₁₋₆alkyl and C₁₋₆alkoxy;

X₁ is -C(-Rx)(-Rx")-, -C(-Rx')(-Rx")-, or -N(Rx)-;

X₂ is -C(-Rx")(-Rx")-, -C(=O)-, -N(-Rx")-, or -O-;



Xs is =O or =NH;

Rx' is haloC₁₋₆alkyl, cyano, nitro, amino, azido, or a 5- to 6-membered
heterocyclyl containing 1 to 2 heteroatoms selected from N and O and unsubstituted or
substituted with oxo;

Rx" is hydrogen, halogen, C₁₋₆alkyl, or C₁₋₄alkoxycarbonyl;

A is benzene or a 5- to 10-membered heteroaryl containing 1 to 3 nitrogen atoms;

B is a monocyclic- or bicyclic-saturated or unsaturated C₆₋₁₀carbocycle or 5- to 10-
membered heterocycle;

L_B is -[C(-R_L)(-R_L')]_m-, -O-, -NH- or -N(C₁₋₆alkyl)-, wherein m is 0 or 1, R_L and
R_L' are each independently hydrogen, hydroxy, halogen or C₁₋₆alkyl, or R_L and R_L' are
linked together to form C₂₋₅alkylene;

R_A is halogen, C₁₋₆alkoxycarbonylamino-C₁₋₆alkoxy, aminoC₁₋₆alkoxy, or 3- to 6-
membered heterocyclyl;

R_B is halogen, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyloxy, C₂₋₆alkenyloxy, C₃₋₁₀
carbocyclyl-oxy, or 3- to 10-membered heterocyclyl-C₁₋₃alkoxy; and

each of said heteroaryl, heterocycle and heterocyclyl moieties independently
contains 1 to 3 heteroatoms selected from the group consisting of O, N and S.

In a preferred embodiment of the compound of formula (I),

X₁ is -N(-Rx)-;

X₂ is -C(-Rx")(-Rx")- or -N(-Rx")-;


Y is -CH=;

Z is -S-;

R_c is =O;

R_N is hydrogen;

L_x is ethylene substituted with one or two R_x'' moieties,



R_x is

X_s is =O;

R_s is methyl;

R_x'' is the same as defined above in formula (I); and

A, B, L_B , R_A , R_B , p and q are the same as defined above in formula (I).

In a preferred embodiment of the compound of formula (I),

X_1 is -CH(- R_x)-;

X_2 is -N(- R_x'')-;


Y is -CH=;

Z is -S-;

R_c is =O;

R_N is hydrogen;

L_x is ethylene;



R_x is

X_s is =O;

R_s is methyl;

R_x'' is the same as defined above in formula (I); and

A, B, L_B , R_A , R_B , p and q are the same as defined above in formula (I).

In a preferred embodiment of the compound of formula (I),

X_1 is -C(- R_x)(- R_x'')-;

X_2 is -O-;


Y is -CH=;

Z is -S-;

R_c is =O;

R_N is hydrogen;

L_x is ethylene;



R_x is

X_s is =O;

R_s is methyl;

R_x'' is the same as defined above in formula (I); and

A, B, L_B, R_A, R_B, p and q are the same as defined above in formula (I).

In a preferred embodiment of the compound of formula (I),

X₁ is -C(-R_{x'})(-R_{x''})-;

X₂ is -O-;

Y is -CH=;

Z is -S-;

R_c is =O;

R_N is hydrogen;

L_x is ethylene;

R_{x'} and R_{x''} are the same defined above in formula (I); and

A, B, L_B, R_A, R_B, p and q are the same as defined above in formula (I).

In a preferred embodiment of the compound of formula (I),

X₁ is -CH(-R_x)-;

X₂ is -C(-R_{x''})(-R_{x'''})- or -C(=O)-;

Y is -CH=;

Z is -S-;

R_c is =O;

R_N is hydrogen;

L_x is ethylene;

R_x is $\begin{array}{c} \text{O} \\ \parallel \\ \text{Rs}-\text{S}-\text{Xs} \\ \parallel \\ \text{Xs} \end{array}$;

X_s is =O;

R_s is methyl;

R_{x''} is the same as defined above in formula (I); and

A, B, L_B, R_A, R_B, p and q are the same as defined above in formula (I).

In a preferred embodiment of the compound of formula (I),

X₁ is -CH(-R_x)-;

X₂ is -C(-R_{x''})(-R_{x'''})-;

Y is -CH=;

Z is -S-;

R_c is =O;

R_N is hydrogen;

L_x is -CH₂-O-;

R_x is $\begin{array}{c} \text{O} \\ \parallel \\ \text{Rs}-\text{S}-\text{Xs} \\ \parallel \\ \text{Xs} \end{array}$;

Xs is =O;

Rs is methyl;

Rx" is the same as defined above in formula (I); and

A, B, L_B, R_A, R_B, p and q are the same as defined above in formula (I).

5

In a preferred embodiment of the compound of formula (I),

X₁ is -C(-Rx)(-Rx")- or -N(Rx)-;

X₂ is -O-;

Y is -NH-;

10

Z is -CH=;

R_c is =O;

R_N is hydrogen;

L_x is propylene;

R_x and R_x" are the same as defined above in formula (I); and

15

A, B, L_B, R_A, R_B, p and q are the same as defined above in formula (I).

Preferable examples of the compound according to the present invention are listed below, and a pharmaceutically acceptable salt and a stereoisomer thereof are also included in the scope of the present invention:

20

1) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide;

2) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide;

25

3) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxamide;

4) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxamide;

5) *tert*-butyl 7-((2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)carbonyl)-1-(methylsulfonyl)-2,3-dihydrothieno[2,3-*g*]quinoxaline-4(1*H*)-carboxylate;

30

6) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxamide;

7) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxamide;

35

8) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

9) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-2,3,4,5-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*]oxepine-8-carboxamide;

10) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide;

40

11) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-(methylsulfonyl)-

- 3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
12) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,8-dihydro-6*H*-thieno[3,2-*g*]isochromene-2-carboxamide;
13) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-(methylsulfonyl)-
5 3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
14) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-8,8-difluoro-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide;
15) *N*-(2-chloro-6-(*p*-tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
10 16) *N*-(2-chloro-6-(3-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
17) *N*-(2-chloro-6-(4-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
18) *N*-(2-chloro-6-(3,5-dichlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-
15 dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
19) *N*-(2-chloro-6-(4-chloro-3-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
20) *N*-(2-chloro-6-(4-chloro-3-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
20 21) *N*-(2-chloro-6-(4-chloro-2-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
22) *N*-(2-chloro-6-(4-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
23) *N*-(2-chloro-6-(4-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-
25 3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
24) *N*-(2-chloro-6-(3,4-dichlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
25 25) *N*-(2-chloro-6-(3-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
30 26) *N*-(2-chloro-6-(4-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
27) *N*-(2-chloro-6-(3-chloro-4-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
28) *N*-(2-chloro-6-(4-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
35 29) *N*-(2-chloro-6-(3-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
30) *N*-(2-chloro-6-(3-chloro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;
40 31) *N*-(2-chloro-6-(3-chloro-5-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

32) *N*-(2-chloro-6-(3-fluoro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

33) *N*-(2-chloro-6-(*m*-tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-

thieno[3,2-*g*]chromene-7-carboxamide;

34) *N*-(2-chloro-6-(3,4-difluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-

dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

35) *N*-(2-chloro-6-(5-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

36) *N*-(2-chloro-6-(3-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

37) *N*-(2-chloro-6-(5-chloro-2-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

38) *N*-(2-chloro-6-(3-chloro-4-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

39) *N*-(2-chloro-6-(2-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

40) *N*-(2-chloro-6-(2-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-

(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

41) *N*-(2-chloro-6-(2-fluoro-3-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

42) *N*-(2-chloro-6-(4-chloro-2-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

43) (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-

dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

44) (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-

dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

45) (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-

(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

46) (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-

(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

47) (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-

(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

48) (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-

(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

49) (*S*)-*N*-(2-chloro-6-(3-chloro-5-methoxyphenoxy)pyridin-4-yl)-4-

(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

50) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-1,2,3,4-

tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxamide;

51) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-8-oxo-

5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide;

52) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

53) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

54) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

55) 4-azido-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide; and

56) *N*-(3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)phenyl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide.

The above-listed names of the compounds are described in accordance with the nomenclature method provided by ChemBioDraw Ultra software (Version 13.0.0.3015) of PerkinElmer.

The present invention provides a pharmaceutically acceptable salt of a heterocyclic derivative represented by formula (I) above. The pharmaceutically acceptable salt should have low toxicity to humans, and should not have any negative impact on the biological activities and physicochemical properties of parent compounds. Examples of the pharmaceutically acceptable salt may include an acid addition salt between a pharmaceutically usable free acid and a basic compound represented by formula (I), an alkaline metal salt (sodium salt, etc.) and an alkaline earth metal salt (potassium salt, etc.), an organic base addition salt between an organic base and carboxylic acid represented by formula (I), amino acid addition salt, etc.

Examples of a suitable form of salts according to the present invention may be a salt with an inorganic acid or organic acid, wherein the inorganic acid may be hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, perchloric acid, bromic acid, etc., and the organic acid may be acetic acid, methanesulfonic acid, ethanesulfonic acid, *p*-toluenesulfonic acid, fumaric acid, maleic acid, malonic acid, phthalic acid, succinic acid, lactic acid, citric acid, gluconic acid, tartaric acid, salicylic acid, malic acid, oxalic acid, benzoic acid, embonic acid, aspartic acid, glutamic acid, etc. The organic base which may be used for the preparation of the organic base addition salt may include tris(hydroxymethyl)methylamine, dicyclohexylamine, etc. Amino acids which may be used for the preparation of amino acid addition base may include natural amino acids such as alanine, and glycine.

The salts may be prepared using a conventional method. For example, the salts may be prepared by dissolving the compound represented by formula (I) in a water-miscible solvent such as methanol, ethanol, acetone, and 1,4-dioxane, adding a free acid or a free base, and then crystallizing the resultant thereafter.

Additionally, the compounds of the present invention may have a chiral carbon center, and thus they may be present in the form of an R or S isomer, a racemic compound, an individual enantiomer or a mixture, an individual diastereomer or a mixture, and all these stereoisomers and a mixture thereof may belong to the scope of the present invention.

5 Additionally, the compounds of the present invention may also include a hydrate or solvate of the heterocyclic derivative represented by formula (I). The hydrate or solvate may be prepared using a known method, and they are preferred to be non-toxic and water-soluble, and in particular, they are preferably water or a hydrate or solvate having 1-5 molecules of alcoholic solvent (especially ethanol, etc.) bound thereto.

10 The present invention also provides a use of a compound selected from the group consisting of a heterocyclic derivative represented by formula (I) above, and a pharmaceutically acceptable salt and a stereoisomer thereof for the manufacture of a medicament for preventing or treating diseases associated with the activation of STAT3 protein.

15 Further, the present invention provides method for preventing or treating diseases associated with the activation of STAT3 protein in a mammal, which comprises administering a compound selected from the group consisting of a heterocyclic derivative represented by formula (I) above, and a pharmaceutically acceptable salt and a stereoisomer thereof to the mammal.

20 Further, the present invention provides a pharmaceutical composition for preventing or treating diseases associated with the activation of STAT3 protein, comprising a compound selected from the group consisting of a heterocyclic derivative represented by formula (I) above, and a pharmaceutically acceptable salt and a stereoisomer thereof as active ingredients.

25 Specifically, the diseases associated with the activation of STAT3 protein is selected from the group consisting of solid cancers, hematological or blood cancers, radio- or chemo-resistant cancers, metastatic cancers, inflammatory diseases, immunological diseases, diabetes, macular degeneration, human papillomavirus infection and tuberculosis.

30 More specifically, the diseases associated with the activation of STAT3 protein are selected from the group consisting of breast cancer, lung cancer, stomach cancer, prostate cancer, uterine cancer, ovarian cancer, kidney cancer, pancreatic cancer, liver cancer, colon cancer, skin cancer, head and neck cancer, thyroid cancer, osteosarcoma, acute or chronic leukemia, multiple myeloma, B- or T-cell lymphoma, non-Hodgkin's lymphoma, auto-immune diseases comprising rheumatoid arthritis, psoriasis, hepatitis, inflammatory bowel disease, Crohn's disease, diabetes, macular degeneration, human papillomavirus infection, and tuberculosis.

40 In particular, a heterocyclic derivative represented by formula (I) above, or a

pharmaceutically acceptable salt or a stereoisomer thereof has an excellent inhibitory effect on the activation of STAT3 protein, and thus the present invention also provides a composition for the inhibition of STAT3 protein comprising the same as an active ingredient.

5

The pharmaceutical composition of the present invention, in addition to the heterocyclic derivative represented by formula (I) above, the pharmaceutically acceptable salt thereof, or the stereoisomer thereof, may further include as active ingredients, common and non-toxic pharmaceutically acceptable additives, for example, a carrier, an excipient, a diluent, an adjuvant, etc., to be formulated into a preparation according to a conventional method.

10

The pharmaceutical composition of the present invention may be formulated into various forms of preparations for oral administration such as tablets, pills, powders, capsules, syrups, or emulsions, or for parenteral administration such as intramuscular, intravenous or subcutaneous injections, etc., and preferably in the form of a preparation for oral administration.

15

Examples of the additives to be used in the pharmaceutical composition of the present invention may include sweeteners, binders, solvents, solubilization aids, wetting agents, emulsifiers, isotonic agents, absorbents, disintegrating agents, antioxidants, preservatives, lubricants, fillers, flavoring agents, etc. For example, they may include, lactose, dextrose, sucrose, mannitol, sorbitol, cellulose, glycine, silica, talc, stearic acid, stearin, magnesium stearate, magnesium aluminosilicate, starch, gelatin, gum tragacanth, alginic acid, sodium alginate, methylcellulose, sodium carboxymethylcellulose, agar, water, ethanol, polyethylene glycol, polyvinylpyrrolidone, sodium chloride, calcium chloride, orange essence, strawberry essence, vanilla flavor, etc.

20

25

The pharmaceutical composition of the present invention may be formulated into a preparation for oral administration by adding additives to active ingredients, wherein the additives may include cellulose, calcium silicate, corn starch, lactose, sucrose, dextrose, calcium phosphate, stearic acid, magnesium stearate, calcium stearate, gelatin, talc, surfactants, suspension agents, emulsifiers, diluents, etc.

30

The pharmaceutical composition of the present invention may be formulated into a preparation for injection by adding additives to the active ingredients, for example, water, a saline solution, a glucose solution, an aqueous glucose solution analog, alcohol, glycol, ether, oil, fatty acid, fatty acid ester, glyceride, surfactants, suspension agents, emulsifiers, etc.

35

The compound of the present invention may be administered preferably in an amount ranging from 0.1 to 2,000 mg/day based on an adult subject with 70 kg body weight. The compound of the present invention may be administered once daily or a few divided doses. The dosage of the compound of the present invention may vary depending

40

on the health conditions, age, body weight, sex of the subject, administration route, severity of illness, etc., and the scope of the present invention will not be limited to the dose suggested above.

5

Example

Hereinafter, the present invention is described more specifically by the following examples, but these are provided only for illustration purposes and the present invention is not limited thereto.

10

The definition of the abbreviations used in the following examples is as follows.

[Table 1]

Abbreviation	Full name
AlCl ₃	Aluminum chloride
ACN	Acetonitrile
AcOH	Acetic acid
AIBN	2,2'-Azobis(2-methylpropionitrile)
BH ₃ -THF complex	Borane tetrahydrofuran complex
BINAP	2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl
BBr ₃	Boron tribromide
Boc ₂ O	Di- <i>tert</i> -butyl dicarbonate
Brine	Brine is water saturated or nearly saturated with a brine salt (generally, sodium chloride)
CH ₃ CN	Acetonitrile
CDCl ₃	Deuterated chloroform
CH ₂ Cl ₂	Dichloromethane
CH ₃ I	Methyl iodide
CH ₃ SO ₂ Cl	Methanesulfonyl chloride
(COCl) ₂	Oxalyl chloride
Cs ₂ CO ₃	Cesium carbonate
Cu ₂ O	Copper (I) oxide
DAST	(Diethylamino)sulfur trifluoride
DIPEA	<i>N,N</i> -diisopropylethylamine
DMA	<i>N,N</i> -dimethylacetamide
DME	1,2-Dimethoxyethane
DMF	<i>N,N</i> -dimethylformamide
DMSO	Dimethylsulfoxide
DMSO- <i>d</i> ₆	Dimethylsulfoxide- <i>d</i> ₆
EtOAc	Ethyl acetate
EtOH	Ethyl alcohol

Et ₂ O	Diethyl ether
HBr	Hydrogen bromide
HCl	Hydrogen chloride
H ₂ SO ₄	Sulfuric acid
<i>n</i> -Hex	<i>n</i> -Hexane
HNO ₃	Nitric acid
H ₂ O	Water
K ₂ CO ₃	Potassium carbonate
LDA	Lithium diisopropylamide
LiOH·H ₂ O	Lithium hydroxide, monohydrate
MeOH	Methyl alcohol
NaBH ₄	Sodium borohydride
NaCN	Sodium cyanide
Na ₂ CO ₃	Sodium carbonate
Na ₂ SO ₄	Sodium sulfate
NaH	Sodium hydride
NaHCO ₃	Sodium bicarbonate
NaOH	Sodium hydroxide
NH ₄ Cl	Ammonium chloride
NFS	<i>N</i> -fluorobenzenesulfonimide
Oxone	Potassium peroxymonosulfate
Pd(PPh ₃) ₄	Tetrakis(triphenylphosphine)palladium(0)
Pd(OAc) ₂	Palladium(II) acetate
PBr ₃	Phosphorus tribromide
PPh ₃	Triphenylphosphine
SOCl ₂	Thionyl chloride
THF	Tetrahydrofuran
TFA	Trifluoroacetic acid
Zn	Zinc

Intermediate 1) Synthesis of 1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylic acid

5

(a) Synthesis of 2-fluoro-4-methoxy-5-nitrobenzaldehyde

2-Fluoro-4-methoxybenzaldehyde (1.0 g, 6.49 mmol) was dissolved in conc. H₂SO₄ (6.0 mL), and 70% HNO₃ aqueous solution (0.8 mL, 6.49 mmol) and conc. H₂SO₄ (0.8 mL, 14.92 mmol) were slowly added at -15°C. The reaction mixture was stirred at -15°C for 2 hours and poured into ice water. The precipitate was filtered and dissolved in CH₂Cl₂ and neutralized with sat. NaHCO₃ aqueous solution. The organic extract was dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, *n*-Hex : CH₂Cl₂ = 3 : 1) to obtain 2-

fluoro-4-methoxy-5-nitrobenzaldehyde (1.2 g, 91%) as a white solid.

¹H-NMR (400MHz, CDCl₃): δ 10.21 (s, 1H), 8.46 (d, 1H, *J*=7.2Hz), 6.88 (d, 1H, *J*=11.6Hz), 4.06 (s, 3H)

5 (b) Synthesis of methyl 6-methoxy-5-nitrobenzo[*b*]thiophene-2-carboxylate

2-Fluoro-4-methoxy-5-nitrobenzaldehyde (1.2 g, 6.43 mmol) was dissolved in anhydrous DMF (16.0 mL), and methyl 2-mercaptoacetate (575.0 μL, 6.43 mmol) and K₂CO₃ (1.8 g, 12.80 mmol) were added. The reaction mixture was stirred at 80°C for 2 hours, H₂O was added, and extracted with EtOAc. The organic extract was washed with
10 brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to obtain methyl 6-methoxy-5-nitrobenzo[*b*]thiophene-2-carboxylate (1.5 g) as a yellow solid without purification.

¹H-NMR (400MHz, CDCl₃): δ 8.34 (s, 1H), 8.03 (s, 1H), 7.47 (s, 1H), 4.04 (s, 3H), 3.96 (s, 3H)

15 (c) Synthesis of methyl 5-amino-6-methoxybenzo[*b*]thiophene-2-carboxylate

Methyl 6-methoxy-5-nitrobenzo[*b*]thiophene-2-carboxylate (1.3 g, 4.83 mmol) was dissolved in a mixture of MeOH/H₂O (44.0 mL, 10/1 v/v), and Zn (3.1 g, 65.30 mmol) and NH₄Cl (2.6 g, 53.40 mmol) were added at room temperature. The reaction mixture
20 was stirred at room temperature for 15 hours, filtered through Celite, and concentrated under reduced pressure. The residue was purified by flash column chromatography (amine silica gel, *n*-Hex : EtOAc = 4 : 1) to obtain methyl-5-amino-6-methoxybenzo[*b*]thiophene-2-carboxylate (1.1 g, 93%) as a yellow solid.

¹H-NMR (400MHz, CDCl₃): δ 7.84 (s, 1H), 7.17 (s, 1H), 7.12 (s, 1H), 3.94-3.96
25 (m, 5H), 3.91 (s, 3H)

(d) Synthesis of methyl 5-amino-6-hydroxybenzo[*b*]thiophene-2-carboxylate

Methyl 5-amino-6-methoxybenzo[*b*]thiophene-2-carboxylate (500.0 mg, 4.83 mmol) was dissolved in CH₂Cl₂ (40.0 mL), and 1M solution of BBr₃ in CH₂Cl₂ (6.7 mL, 6.74 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for
30 30 minutes, H₂O was added, and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain methyl 5-amino-6-hydroxybenzo[*b*]thiophene-2-carboxylate (398.0 mg, 85%) as a gray solid.

LC/MS ESI (+): 224 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 10.15 (brs, 1H), 7.85 (s, 1H), 7.15 (s, 1H), 7.07 (s, 1H), 4.86 (brs, 2H) 3.82 (s, 3H)

40 (e) Synthesis of methyl 2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-

7-carboxylate

Methyl 5-amino-6-hydroxybenzo[*b*]thiophene-2-carboxylate (85.0 mg, 0.38 mmol) was dissolved in anhydrous DMF (3.8 mL), and 1,2-dibromoethane (215.0 mg, 1.14 mmol) and K₂CO₃ (116.0 mg, 0.83 mmol) were added at room temperature. The reaction mixture was stirred at 75°C for 15 hours, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain methyl 2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (45.2 mg, 47%) as a gray solid.

LC/MS ESI (+): 250 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 7.89 (s, 1H), 7.26 (s, 1H), 7.07 (s, 1H), 6.16 (s, 1H), 4.19 (t, 2H, *J* = 4.6Hz), 3.82 (s, 3H), 3.30-3.32 (m, 2H)

(f) Synthesis of methyl 1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate

Methyl 2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (69.0 mg, 0.27 mmol) was dissolved in CH₂Cl₂ (2.7 mL), CH₃SO₂Cl (28.0 μL, 0.36 mmol) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 1 hour, H₂O was added, and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain methyl 1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (42.3 mg, 46%) as a white solid.

LC/MS ESI (+): 328 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.21 (s, 1H), 8.12 (s, 1H), 7.63 (s, 1H), 4.35 (t, 2H, *J* = 4.3Hz), 3.86- 3.89 (m, 5H), 3.17 (s, 3H)

(g) Synthesis of 1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylic acid

The synthesis procedure of Intermediate 1-g was repeated except for using methyl 1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (42.0 mg, 0.12 mmol) to obtain 1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylic acid (35.1 mg, 87%) as a white solid.

LC/MS ESI (-): 312 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.32 (brs, 1H), 8.18 (s, 1H), 8.00 (s, 1H), 7.60 (s, 1H), 4.36 (t, 2H, *J* = 4.7Hz), 3.89 (t, 2H, *J* = 4.7Hz), 3.18 (s, 3H)

Intermediate 2) Synthesis of 3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1H-thieno[3',2':4,5]benzo[1,2-b][1,4]oxazine-7-carboxylic acid

5 (a) Synthesis of methyl 5-(2-bromo-2-methylpropanamido)-6-hydroxybenzo[*b*]thiophene-2-carboxylate

Methyl 5-amino-6-hydroxybenzo[*b*]thiophene-2-carboxylate (110.0 mg, 0.49 mmol) was dissolved in DMA (5.0 mL), and 2-bromo-2-methyl propanoyl bromide (73.0 μ L, 0.59 mmol) and DIPEA (258.0 μ L, 1.47 mmol) were added. The reaction mixture
10 was stirred at room temperature for 3 hours, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain methyl 5-(2-bromo-2-methylpropanamido)-6-hydroxybenzo[*b*]thiophene-2-
15 carboxylate (161.0 mg, 88%) as a white solid.

LC/MS ESI (+): 372 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 11.15 (brs, 1H), 9.24 (s, 1H), 8.49 (s, 1H), 8.08 (s, 1H), 7.43 (s, 1H), 3.85 (s, 3H), 2.03 (s, 6H)

20 (b) Synthesis of methyl 3,3-dimethyl-2-oxo-2,3-dihydro-1H-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate

Methyl 5-(2-bromo-2-methylpropanamido)-6-hydroxybenzo[*b*]thiophene-2-carboxylate (161.0 mg, 0.43 mmol) was dissolved in DMA (4.3 mL) and K₂CO₃ (132.0 mg, 0.95 mmol) was added. The reaction mixture was stirred at 60°C for 15 hours, H₂O
25 was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain methyl 3,3-dimethyl-2-oxo-2,3-dihydro-1H-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (112.0 mg, 89%) as a gray solid.

30 LC/MS ESI (-): 290 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 10.95 (s, 1H), 8.14 (s, 1H), 7.66 (s, 1H), 7.46 (s, 1H), 3.86 (s, 3H), 1.44 (s, 6H)

(c) Synthesis of methyl 3,3-dimethyl-2,3-dihydro-1H-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate

35 Methyl 3,3-dimethyl-2-oxo-2,3-dihydro-1H-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (112.0 mg, 0.38 mmol) was dissolved in THF (4.0 mL), and 1M solution of BH₃-THF complex (1.9 mL, 1.92 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 3 hours, H₂O was added, and extracted with
40 EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and

concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 3,3-dimethyl-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (80.0 mg, 75%) as a gray solid.

5 LC/MS ESI (+): 278 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 7.90 (s, 1H), 7.23 (s, 1H), 7.11 (s, 1H), 6.26 (brs, 1H), 3.83 (s, 3H) 3.06 (d, 2H, *J*=2.3Hz), 1.29 (s, 6H)

10 (d) Synthesis of methyl 3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate

Methyl 3,3-dimethyl-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (65.0 mg, 0.88 mmol) was dissolved in pyridine (2.3 mL) and CH₃SO₂Cl (95.0 μL, 1.06 mmol) was added dropwise at 0°C. The reaction mixture was stirred at room temperature for 15 hours, H₂O was added, and extracted with EtOAc. The organic extract
15 was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain methyl 3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (52.2 mg, 63%) as a white solid.

20 LC/MS ESI (+): 356 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.20 (s, 1H), 8.11 (s, 1H), 7.56 (s, 1H), 3.87 (s, 3H), 3.67 (s, 2H), 3.37 (s, 3H), 1.36 (s, 6H)

25 (e) Synthesis of 3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylic acid

The synthesis procedure of Intermediate 1-g was repeated except for using methyl 3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylate (52.0 mg, 0.14 mmol) as a starting material to obtain 3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-
30 carboxylic acid (45.0 mg, 90%).

LC/MS ESI (+): 342 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.30 (s, 1H), 8.17 (s, 1H), 8.01 (s, 1H), 7.53 (s, 1H), 3.66 (s, 2H), 3.34 (s, 3H), 1.36 (s, 6H)

35

Intermediate 3) Synthesis of 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxylic acid

40 (a) Synthesis of methyl 6-hydroxy-5-(methylsulfonamido)benzo[*b*]thiophene-2-carboxylate

Methyl 5-amino-6-hydroxybenzo[*b*]thiophene-2-carboxylate (126.0 mg, 0.56 mmol) was dissolved in pyridine (2.8 mL), and CH₃SO₂Cl (50.6 μL, 0.64 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 2 hours, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain methyl 6-hydroxy-5-(methylsulfonamido)benzo[*b*]thiophene-2-carboxylate (131.0 mg, 77%) as a white solid.

LC/MS ESI (-): 300 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 9.92 (brs, 1H), 8.08 (s, 1H), 7.85 (s, 1H), 7.43 (s, 1H), 3.86 (s, 3H), 2.99 (s, 3H)

(b) Synthesis of methyl 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxylate

Methyl 6-hydroxy-5-(methylsulfonamido)benzo[*b*]thiophene-2-carboxylate (5.0 mg, 0.02 mmol) as a starting material was dissolved in DMA (160.0 μL), and 1,3-dibromopropane (16.7 mg, 0.08 mmol) and K₂CO₃ (116.0 mg, 0.83 mmol) were added. The reaction mixture was stirred at room temperature for 15 hours, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, *n*-Hex : EtOAc = 2 : 1) to obtain methyl 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxylate (1.2 mg, 21%) as a white solid.

LC/MS ESI (+): 342 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.20 (s, 1H), 8.07 (s, 1H), 7.86 (s, 1H), 4.13-4.15 (m, 2H), 3.89 (s, 3H), 3.72-3.75 (m, 2H), 3.09 (s, 3H), 2.04-2.07 (m, 2H)

(c) Synthesis of 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxylic acid

The synthesis procedure of Intermediate 1-g was repeated except for using methyl 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxylate (42.0 mg, 0.12 mmol) as a starting material to obtain 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxylic acid (22.3 mg, 55%).

LC/MS ESI (+): 328 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.52 (brs, 1H), 8.09 (s, 1H), 8.04 (s, 1H), 7.83 (s, 1H), 4.12-4.14 (m, 2H), 3.73-3.75 (m, 2H), 3.09 (s, 3H), 1.99-2.07 (m, 2H)

Intermediate 4) Synthesis of 8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-

tetrahydrothieno[2,3-g]quinoline-2-carboxylic acid**(a) Synthesis of ethyl 5-(3-methylbut-2-enamido)benzo[*b*]thiophene-2-carboxylate**

Ethyl 5-aminobenzo[*b*]thiophene-2-carboxylate (1.5 g, 6.78 mmol) was dissolved in pyridine (33.9 mL), and 3-methylbut-2-enoyl chloride (755.0 μ L, 6.78 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, *n*-Hex : EtOAc = 9 : 1) to obtain ethyl 5-(3-methylbut-2-enamido)benzo[*b*]thiophene-2-carboxylate (1.3 g, 63%) as a colorless liquid.

¹H-NMR (400MHz, CDCl₃): δ 8.29 (s, 1H), 7.99 (s, 1H), 7.77 (d, 1H, *J*=8.7Hz), 7.44 (d, 1H, *J*=8.6Hz), 7.17 (s, 1H), 5.74 (s, 1H), 4.40 (q, 2H, *J*=7.1Hz), 2.26 (s, 3H), 1.93 (s, 3H), 1.41 (t, 3H, *J*=7.1Hz)

(b) Synthesis of ethyl 8,8-dimethyl-6-oxo-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate

Ethyl 5-(3-methylbut-2-enamido)benzo[*b*]thiophene-2-carboxylate (1.3 g, 4.29 mmol) was dissolved in CH₂Cl₂ (42.9 mL), and AlCl₃ (1.7 g, 12.86 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 2 hours, H₂O was added, and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain ethyl 8,8-dimethyl-6-oxo-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate (250.0 mg, 19%) as a yellow solid.

¹H-NMR (400MHz, CDCl₃): δ 8.44 (s, 1H), 8.41 (s, 1H), 7.94 (s, 1H), 7.76 (s, 1H), 4.42 (q, 2H, *J*=7.1Hz), 2.55 (s, 2H), 1.59 (s, 6H), 1.43 (t, 3H, *J*=7.1Hz)

(c) Synthesis of ethyl 8,8-dimethyl-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate

The synthesis procedure of Intermediate 15-c was repeated except for using ethyl 8,8-dimethyl-6-oxo-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate (217.0 mg, 0.72 mmol) as a starting material to obtain ethyl 8,8-dimethyl-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate (56.0 mg, 27%).

¹H-NMR (400MHz, CDCl₃): δ 7.78 (s, 1H), 7.63 (s, 1H), 6.88 (s, 1H), 4.37 (q, 2H, *J*=7.1Hz), 3.37 (t, 2H, *J*=5.8Hz), 1.78 (t, 2H, *J*=5.8Hz), 1.37-1.41 (m, 9H)

(d) Synthesis of ethyl 8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate

The synthesis procedure of Intermediate 16-f was repeated except for using ethyl 8,8-dimethyl-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate (56.0 mg, 0.19 mmol)

as a starting material to obtain ethyl 8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate (57.0 mg, 80%).

¹H-NMR (400MHz, CDCl₃): δ 8.21 (s, 1H), 7.97 (s, 1H), 7.83 (s, 1H), 4.40 (q, 2H, *J*=7.1Hz), 3.90 (t, 2H, *J*=5.8Hz), 2.92 (s, 3H), 1.88 (t, 2H, *J*=5.8Hz), 1.39-1.43 (m, 9H)

(e) Synthesis of 8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylic acid

The synthesis procedure of Intermediate 1-g was repeated except for using ethyl 8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylate (57.0 mg, 0.16 mmol) as a starting material to obtain 8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-g]quinoline-2-carboxylic acid (52.0 mg, 80%).

LC/MS ESI (+): 340 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 8.25 (s, 1H), 8.08 (s, 1H), 7.87 (s, 1H), 3.91 (t, 2H, *J*=5.8Hz), 2.94 (s, 3H), 1.89 (t, 2H, *J*=5.8Hz), 1.43 (s, 6H)

Intermediate 5) Synthesis of 4-(tert-butoxycarbonyl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-g]quinoxaline-7-carboxylic acid

(a) Synthesis of 4-bromo-2-fluoro-5-nitrobenzaldehyde

4-bromo-2-fluorobenzaldehyde (2.0 g, 9.85 mmol) was dissolved in conc. H₂SO₄ (5.2 mL, 98.50 mmol), and 60% HNO₃ (1.0 mL, 12.80 mmol) was added at 0°C. The reaction mixture was stirred for 4 hours, and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was recrystallized using *i*-Pr₂O to obtain 4-bromo-2-fluoro-5-nitrobenzaldehyde (900.0 mg, 37%) as a white solid.

¹H-NMR (400MHz, CDCl₃): δ 10.31 (s, 1H), 8.42 (d, 1H, *J*=6.4Hz), 7.67 (d, 1H, *J*=9.0Hz).

(b) Synthesis of methyl 6-bromo-5-nitrobenzo[*b*]thiophene-2-carboxylate

4-bromo-2-fluoro-5-nitrobenzaldehyde (5.0 g, 20.10 mmol) was dissolved in anhydrous DMF (50.0 mL), and methyl 2-mercaptoacetate (2.1 g, 20.10 mmol) and K₂CO₃ (5.6 g, 40.30 mmol) were added, followed by heating at 80°C for 2 hours. The reaction mixture was cooled to room temperature and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 6-bromo-5-nitrobenzo[*b*]thiophene-2-carboxylate (3.4 g, 53%) as a yellow solid.

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.38 (s, 1H), 8.23 (s, 1H), 8.09 (s, 1H), 3.98 (s, 3H)

(c) Synthesis of methyl 6-amino-5-nitrobenzo[*b*]thiophene-2-carboxylate

6-bromo-5-nitrobenzo[*b*]thiophene-2-carboxylate (3.0 g, 9.49 mmol) was dissolved in DMSO (10.0 ml) and Cu₂O (830.0 mg, 10.40 mmol), sodium azide (1.2 g, 18.90 mmol) were added at room temperature. The mixture was stirred at 100 °C for 1 hour and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 6-amino-5-nitrobenzo[*b*]thiophene-2-carboxylate (1.6 g, 66%) as an off-white solid.

LC/MS ESI (+): 253 (M+1)

¹H-NMR(400MHz, CDCl₃): δ 8.77 (s, 1H), 8.11 (s, 1H), 7.44 (s, 1H), 7.39 (s, 2H), 3.33 (s, 3H)

(d) Synthesis of methyl 6-((*tert*-butoxycarbonyl)amino)-5-nitrobenzo[*b*]thiophene-2-carboxylate

Methyl 6-amino-5-nitrobenzo[*b*]thiophene-2-carboxylate (800.0 mg, 3.17 mmol) was dissolved in DMA (10.0 mL) and Boc₂O (831.0 mg, 3.81 mmol), DIPEA (1.6 mL, 9.51 mmol) were added at room temperature. The mixture was stirred at 100 °C for 2 hours and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 6-((*tert*-butoxycarbonyl)amino)-5-nitrobenzo[*b*]thiophene-2-carboxylate (663.0 mg, 59%), as an off-white solid.

¹H-NMR(400MHz, CDCl₃): δ 9.59 (s, 1H), 8.74 (s, 1H), 8.32 (s, 1H), 8.31 (s, 1H), 3.91 (s, 3H), 1.46 (s, 9H)

(e) Synthesis of methyl 5-amino-6-((*tert*-butoxycarbonyl)amino)benzo[*b*]thiophene-2-carboxylate

Methyl 6-((*tert*-butoxycarbonyl)amino)-5-nitrobenzo[*b*]thiophene-2-carboxylate (662.0 mg, 1.87 mmol) was dissolved in a mixture solvent of MeOH/H₂O (20.0 mL, 9/1 v/v), and Zn (18.7 g, 18.70 mmol) and NH₄Cl (1.0 g, 18.70 mmol) were added thereto, and an ultrasonic reaction was conducted at 30°C for 15 hours. The reaction mixture was filtered through Celite and concentrated under a reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 5-amino-6-((*tert*-butoxycarbonyl) amino) benzo[*b*]thiophene-2-carboxylate (633.0 mg, 104%) as an off-white solid.

LC/MS ESI (+): 323 (M+1)

¹H-NMR(400MHz, CDCl₃): δ 8.56 (s, 1H), 8.01 (s, 1H), 7.92 (s, 1H), 7.21 (s, 1H), 5.14 (s, 2H), 3.85 (s, 3H), 1.50 (s, 9H)

(f) Synthesis of methyl 6-((*tert*-butoxycarbonyl)amino)-5-(methylsulfonamido)benzo[*b*]thiophene-2-carboxylate

Methyl 5-amino-6-((*tert*-butoxycarbonyl) amino) benzo [*b*]thiophene-2-carboxylate (633.0 mg, 1.96 mmol) was dissolved in pyridine (9.8 mL), and
5 methanesulfonyl chloride (168.0 μ L, 2.16 mmol) was slowly added thereto at 0°C. The reaction mixture was warmed to room temperature, followed by stirred for 3 hours and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic
10 acid in H₂O) to obtain methyl 6-((*tert*-butoxycarbonyl)amino)-5-(methylsulfonamido)benzo[*b*]thiophene-2-carboxylate (694.0 mg, 88%), as an off-white solid.

LC/MS ESI (-): 399 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 9.28 (s, 1H), 8.55 (s, 1H), 8.41 (s, 1H), 8.16 (s,
15 1H), 7.99 (s, 1H), 3.89 (s, 3H), 3.02 (s, 3H), 1.51 (s, 9H)

(g) Synthesis of 4-(*tert*-butyl) 7-methyl 1-(methylsulfonyl)-2,3-dihydrothieno[2,3-*g*]quinoxaline-4,7(1*H*)-dicarboxylate

Methyl 6-((*tert*-butoxycarbonyl)amino)-5-(methylsulfonamido)
20 benzo[*b*]thiophene-2-carboxylate (684.0 mg, 1.70 mmol) was dissolved in DMA (17.1 mL), and 1,2-dibromoethane (963.0 mg, 5.12 mmol) and K₂CO₃ (472.0 mg, 3.42 mmol) were slowly added at room temperature. The mixture was stirred for 1 hour, and the reaction mixture was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by
25 reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 4-(*tert*-butyl) 7-methyl 1-(methylsulfonyl)-2,3-dihydrothieno[2,3-*g*]quinoxaline-4,7(1*H*)-dicarboxylate (495.0 mg, 68%), as an off-white solid.

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.42 (s, 1H), 8.17 (s, 1H), 8.12 (s, 1H), 3.85-
30 3.92 (m, 4H), 3.89 (s, 3H), 3.12 (s, 3H), 1.51 (s, 9H)

(h) Synthesis of 4-(*tert*-butoxycarbonyl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylic acid

4-(*tert*-butyl) 7-methyl 1-(methylsulfonyl)-2,3-dihydrothieno[2,3-*g*]quinoxaline-
35 4,7(1*H*)-dicarboxylate (495.0 mg, 1.16 mmol) was dissolved in THF/H₂O (10.0 mL, 3/1 v/v), and LiOH·H₂O (146.0 mg, 3.48 mmol) was added. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under a reduced pressure. The residue was diluted in H₂O (1.0 mL), and acidified with 1N HCl (pH 1-2). The precipitate was filtered to obtain 4-(*tert*-butoxycarbonyl)-1-(methylsulfonyl)-1,2,3,4-
40 tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylic acid (422.0 mg, 88%) as a white solid.

LC/MS ESI (-): 411 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.47 (brs, 1H), 8.37 (s, 1H), 8.09 (s, 1H), 8.05 (s, 1H), 3.83 ~ 3.92 (m, 4H), 3.11 (s, 3H), 1.50 (s, 9H)

5 **Intermediate 6) Synthesis of 5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylic acid**

(a) Synthesis of methyl (*E*)-6-(3-methoxy-3-oxoprop-1-en-1-yl)-5-nitrobenzo[*b*]thiophene-2-carboxylate

10 Methyl 6-bromo-5-nitrobenzo[*b*]thiophene-2-carboxylate (0.4 g, 1.26 mmol) was dissolved in anhydrous DMF(12.6 ml), and Pd(OAc)₂ (28.0 mg, 0.13 mmol), PPh₃ (66.0 mg, 0.25 mmol), TEA (0.4 ml, 2.53 mmol) and methyl acrylate (0.6 ml, 6.33 mmol) were added. The reaction mixture was stirred at 130°C for 30 minutes, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated
15 under reduced pressure. The residue was recrystallized with diethyl ether to obtain methyl (*E*)-6-(3-methoxy-3-oxoprop-1-en-1-yl)-5-nitrobenzo[*b*]thiophene-2-carboxylate as a white solid.

LC/MS ESI (+): 322 (M+1)

20 ¹H-NMR (400MHz, CDCl₃): δ 8.62 (s, 1H), 8.16-8.22 (m, 2H), 8.09 (s, 1H), 6.43 (d, 1H, *J*=16.0Hz), 4.00 (s, 3H), 3.85 (s, 3H)

(b) Synthesis of methyl 6-oxo-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate

25 (*E*)-methyl 6-(3-methoxy-3-oxoprop-1-en-1-yl)-5-nitrobenzo[*b*]thiophene-2-carboxylate (0.2 g, 0.62 mmol) was dissolved in anhydrous MeOH(15.6 mL), and 5% Pd-C (20.0 mg, 0.19 mmol) was added. The reaction mixture was charged with H₂ gas and stirred at 25°C for 4 days. The residue was filtered through Celite and concentrated under reduced pressure to obtain methyl 6-oxo-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate (100.0 mg, 61%) as a white solid without purification.

30 LC/MS ESI (+): 262 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.95 (s, 1H), 7.80 (brs, 1H), 7.66 (s, 1H), 7.21 (s, 1H), 3.94 (s, 3H), 3.11 (t, 2H, *J*=7.2Hz), 2.69 (t, 2H, *J*=7.2Hz)

(c) Synthesis of methyl 5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate

35 Methyl 6-oxo-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate (100.0 mg, 0.38 mmol) was dissolved in THF (4.0 mL), and 1M solution of BH₃-THF complex (1.9 mL, 1.91 mmol) was added at 0°C. The reaction mixture was stirred at room temperature for 3 hours, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The
40 residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1%

formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate (65.0 mg, 69%) as a gray solid.

LC/MS ESI (+): 248 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.80 (s, 1H), 7.40 (s, 1H), 6.89 (s, 1H), 3.91 (s, 3H), 3.35 (t, 2H, *J*=5.3Hz), 2.92 (t, 2H, *J*=6.3Hz), 1.96-1.99 (m, 2H)

(d) Synthesis of methyl 5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate

Methyl 5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate (50.0 mg, 0.20 mmol) was dissolved in CH₂Cl₂ (2.0 mL), and CH₃SO₂Cl (23.6 μL, 0.30 mmol) and DIPEA (70.6 μL, 0.40 mmol) were added at 0°C. The reaction mixture was stirred for 3 hours and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under a reduced pressure. The residue was purified by flash column chromatography (silica gel, n-Hex : EtOAc = 2 : 1) to obtain methyl 5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate (57.0 mg, 87%) as a white solid.

LC/MS ESI (+): 326 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 8.21 (s, 1H), 7.99 (s, 1H), 7.63 (s, 1H), 3.94 (s, 3H), 3.87 (t, 2H, *J*=6.0Hz), 2.99 (t, 2H, *J*=6.0Hz), 2.90 (s, 3H), 2.04-2.07 (m, 2H)

(e) Synthesis of 5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylic acid

The synthesis procedure of Intermediate 5-h was repeated except for using methyl 5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylate (60.0 mg, 0.18 mmol) to obtain 5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxylic acid (450.0 mg, 87 %), as a white solid.

LC/MS ESI (+): 312 (M+1)

Intermediate 7) Synthesis of 4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylic acid

(a) Synthesis of methyl 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylate

Unpurified *tert*-butyl 7-(chlorocarbonyl)-1-(methylsulfonyl)-2,3-dihydrothieno[2,3-*g*]quinoxaline-4(1*H*)-carboxylate (40.0 mg, 0.09 mmol) was dissolved in CH₂Cl₂/MeOH (1.6 mL, 1/1 v/v), and TFA (0.3 mL) was slowly added. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylate (21.0 mg,

69%) as a white solid.

LC/MS ESI (+): 327 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 7.97 (s, 1H), 7.90 (s, 1H), 7.09 (s, 1H), 7.00 (s, 1H), 3.82 (s, 3H), 3.67-3.69 (m, 2H), 3.43-3.45 (m, 2H), 3.00 (s, 3H)

(b) Synthesis of methyl 4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylate

Methyl 1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylate (63.0 mg, 0.19 mmol) was dissolved in MeOH (1.9 mL), and formaldehyde (76.0 μL, 0.96 mmol) and sodium cyanoborohydride (36.4 mg, 0.57 mmol) and AcOH (11.0 μL, 0.19 mmol) were added thereto at room temperature. The mixture was stirred for 15 hours, and the reaction mixture was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under a reduced pressure. The residue was separated on reversed-phase silica by column chromatography (0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O = 70 : 30), and fractions including the product were combined and evaporated to obtain methyl 4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylate (51.0 mg, 78%) as a white solid.

LC/MS ESI (+): 341 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.00 (s, 1H), 7.90 (s, 1H), 7.28 (s, 1H), 3.84 (s, 3H), 3.76 (t, 2H, *J*=5.3Hz), 3.51 (t, 2H, *J*=5.3Hz), 3.02 (s, 3H), 3.01 (s, 3H)

(c) Synthesis of 4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylic acid

Methyl 4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylate (50.0 mg, 0.14 mmol) was dissolved in THF/H₂O (1.5 mL, 3/1 v/v), and LiOH·H₂O (18.4 mg, 0.44 mmol) was added thereto. After stirring at room temperature for 2 hours, the reaction mixture was concentrated under a reduced pressure. The residue was diluted in H₂O (1.0 mL), and acidified with 1N HCl (pH 1-2). The precipitate was filtered to obtain 4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxylic acid (42.0 mg, 88%) as a white solid.

LC/MS ESI (+): 327 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.02 (brs, 1H), 7.89 (s, 1H), 7.87 (s, 1H), 7.26 (s, 1H), 3.76 (t, 2H, *J*=5.4Hz), 3.50 (t, 2H, *J*=5.4Hz), 3.01 (s, 3H), 3.00 (s, 3H)

Intermediate 8) Synthesis of 4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

(a) Synthesis of 2-chloro-4-(3,3-diethoxypropoxy)-1-methylbenzene

3-Chloro-4-methylphenol (3.0 g, 21.04 mmol) was dissolved in anhydrous DMF

(105.0 mL), and 3-chloro-1,1-diethoxypropane (4.2 g, 25.20 mmol) and K₂CO₃ (8.7 g, 63.10 mmol) were added. The reaction mixture was stirred at 80°C for 15 hours, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, n-Hex : EtOAc = 95 : 5) to obtain 2-chloro-4-(3,3-diethoxypropoxy)-1-methylbenzene (4.0 g, 69%) as a colorless liquid.

¹H-NMR (400MHz, CDCl₃): δ 7.16 (d, 1H, *J*=8.4Hz), 6.91 (d, 1H, *J*=2.6Hz), 6.71 (dd, 1H, *J*=8.4Hz, 2.6Hz), 4.75 (t, 1H, *J*=5.7Hz), 4.1 (t, 2H, *J*=6.3Hz), 3.66-3.73 (m, 2H), 3.49-3.57 (m, 2H), 2.29 (s, 3H), 2.05-2.10 (m, 2H), 1.22 (t, 6H, *J*=7.1Hz).

(b) Synthesis of 7-chloro-6-methyl-4-(methylsulfonyl)chromane

Sodium methane sulfinat (4.5 g, 44.00 mmol) was dissolved in TFA (61.1 mL) and stirred at 0°C for 10 minutes. A solution of 2-chloro-4-(3,3-diethoxypropoxy)-1-methylbenzene (4.0 g, 14.66 mmol) in CH₂Cl₂ (12.2 mL) was added to the reaction mixture for a period of 1 hour, and stirred at room temperature for 30 minutes. The reaction mixture was basified with sat. NaHCO₃ aqueous solution (pH=9-10), and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, n-Hex : EtOAc = 1 : 2) to obtain 7-chloro-6-methyl-4-(methylsulfonyl)chromane (2.3 g, 60%) as an off-white solid.

¹H-NMR (400MHz, CDCl₃): δ 7.36 (s, 1H), 6.95 (s, 1H), 4.40-4.46 (m, 1H), 4.17-4.25 (m, 2H), 2.83 (s, 3H), 2.55-2.62 (m, 1H), 2.32-2.42 (m, 1H), 2.31 (s, 3H).

(c) Synthesis of 6-(bromomethyl)-7-chloro-4-(methylsulfonyl)chromane

7-Chloro-6-methyl-4-(methylsulfonyl)chromane (2.3 g, 8.63 mmol) was dissolved in anhydrous 1,2-dichloroethane (86.0 mL), and *N*-bromosuccinimide (1.5 g, 8.63 mmol) and AIBN (142.0 mg, 0.86 mmol) were added. The reaction mixture was refluxed at 100°C for 15 hours, cooled to room temperature, H₂O was added, and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by flash column chromatography (silica gel, n-Hex : EtOAc = 4 : 1) to obtain 6-(bromomethyl)-7-chloro-4-(methylsulfonyl)chromane (2.5 g, 85%) as a yellow solid.

¹H-NMR (400MHz, CDCl₃): δ 7.59 (s, 1H), 7.00 (s, 1H), 4.47-4.62 (m, 3H), 4.25-4.31 (m, 1H), 4.19-4.22 (m, 1H), 2.87 (s, 3H), 2.56-2.62 (m, 1H), 2.34-2.43 (m, 1H).

(d) Synthesis of 7-chloro-4-(methylsulfonyl)chromane-6-carbaldehyde

6-(Bromomethyl)-7-chloro-4-(methylsulfonyl)chromane (2.5 g, 7.36 mmol) was dissolved in anhydrous CH₃CN (73.6 mL), and 4-methylmorpholine *N*-oxide (1.7 g, 14.72 mmol) and a molecular sieve (3.0 g) were added. The reaction mixture was stirred at room temperature for 2 hours, H₂O was added to the reaction mixture, and extracted with

EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was recrystallized with Et₂O to obtain 7-chloro-4-(methylsulfonyl)chromane-6-carbaldehyde (1.3 g, 64%) as a pale yellow solid.

LC/MS ESI (+): 275 (M+1).

¹H-NMR (400MHz, CDCl₃): δ 10.32 (s, 1H), 7.97 (s, 1H), 7.03 (s, 1H), 4.64-4.71 (m, 1H), 4.39-4.44 (m, 1H), 4.23 (m, 1H), 2.99 (s, 3H), 2.73-2.78 (m, 1H), 2.30-2.34 (m, 1H).

(e) Synthesis of methyl 4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate

7-Chloro-4-(methylsulfonyl)chromane-6-carbaldehyde (300.0 mg, 1.09 mmol) was dissolved in anhydrous DMF (10.0 mL), and methyl 2-mercapto acetate (117.0 μL, 1.31 mmol) and Cs₂CO₃ (1.1 g, 3.28 mmol) were added. The reaction mixture was stirred at 80°C for 4 hours, cooled to room temperature, H₂O was added, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was recrystallized with CH₂Cl₂ and Et₂O to obtain methyl 4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (200.0 mg, 56%) as a white solid.

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.17 (s, 1H), 8.09 (s, 1H), 7.57 (s, 1H), 4.82 (m, 1H), 4.45-4.50 (m, 1H), 4.31-4.35 (m, 1H), 3.88 (s, 3H), 3.17 (s, 3H), 2.59-2.69 (m, 1H), 2.26-2.37 (m, 1H).

LC/MS ESI (+): 327 (M+1).

(f) Synthesis of 4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

Methyl 4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (200.0 mg, 0.61 mmol) was dissolved in THF (4.0 mL)/H₂O (2.0 mL), and LiOH·H₂O (257.0 mg, 6.13 mmol) was added. The reaction mixture was stirred at 60°C for 15 hours, 1N HCl (3.0 mL) was added, and extracted with CH₂Cl₂ and MeOH. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to obtain 4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid (140.0 mg, 73%) as an off-white solid.

LC/MS ESI (-): 311 (M-1).

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.34 (bs, 1H), 8.06 (s, 2H), 7.54 (s, 1H), 4.82 (m, 1H), 4.45-4.54 (m, 1H), 4.30-4.34 (m, 1H), 3.16 (s, 3H), 2.60-2.74 (m, 1H), 2.28-2.39 (m, 1H).

Intermediate 9) Synthesis of 5-(methylsulfonyl)-2,3,4,5-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*]oxepine-8-carboxylic acid

(a) Synthesis of 2-chloro-4-(4,4-diethoxybutoxy)-1-methylbenzene

The synthesis procedure of Intermediate 8-a was repeated except for using 3-chloro-4-methylphenol (1.0 g, 7.01 mmol) to obtain 2-chloro-4-(4,4-diethoxybutoxy)-1-methylbenzene (1.8 g, 89 %) as a colorless liquid.

LC/MS ESI (+): 287 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.09 (d, 1H, *J*=8.0Hz), 6.89 (d, 1H, *J*=2.8Hz), 6.69 (dd, 1H, *J*=8.6, 2.8Hz), 4.54 (t, 1H, *J*=1.6Hz), 3.93 (t, 2H, *J*=6.0Hz), 3.62-3.70 (m, 2H), 3.47-3.54 (m, 2H), 2.28 (s, 3H), 1.74-1.87 (m, 4H), 1.21 (t, 6H, *J*=7.2Hz)

(b) Synthesis of 8-chloro-7-methyl-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine

The synthesis procedure of Intermediate 8-b was repeated except for using 2-chloro-4-(4,4-diethoxybutoxy)-1-methylbenzene (1.8 g, 6.20 mmol) to obtain 8-chloro-7-methyl-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine (421.0 mg, 23%) as a white solid.

LC/MS ESI (+): 275 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.20 (s, 1H), 7.10 (s, 1H), 4.34-4.39 (m, 1H), 4.16 (t, 1H, *J*=1.6Hz), 3.71-3.77 (m, 1H), 2.78 (s, 3H), 2.64-2.70 (m, 1H), 2.33 (s, 3H), 2.22-2.29 (m, 1H), 2.07-2.15 (m, 1H), 1.82-1.89 (m, 1H).

(c) Synthesis of 7-(bromomethyl)-8-chloro-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine

The synthesis procedure of Intermediate 8-c was repeated except for using 8-chloro-7-methyl-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine (421 mg, 1.53 mmol) to obtain 7-(bromomethyl)-8-chloro-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine (342.0 mg, 63%) as a white solid.

LC/MS ESI (+): 353 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.42 (s, 1H), 7.15 (s, 1H), 4.44 (m, 2H), 4.39-4.44 (m, 1H), 4.20 (t, 1H, *J*=1.6Hz), 3.76-3.82 (m, 1H), 2.78 (s, 3H), 2.68-2.72 (m, 1H), 2.28-2.38 (m, 1H), 2.09-2.18 (m, 1H), 1.86-1.94 (m, 1H)

(d) Synthesis of 8-chloro-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine-7-carbaldehyde

The synthesis procedure of Intermediate 8-d was repeated except for using 7-(bromomethyl)-8-chloro-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine (342.0mg, 0.97 mmol) to obtain 8-chloro-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine-7-carbaldehyde (164.0 mg, 57%), as a white solid.

LC/MS ESI (+): 289 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 10.36 (s, 1H), 7.89 (s, 1H), 7.21 (s, 1H), 4.55-4.59 (m, 1H), 4.31 (t, 1H, *J*=1.6Hz), 3.78-3.84 (m, 1H), 2.79-2.84 (m, 4H), 2.42-2.53 (m, 1H),

2.02-2.11 (m, 1H), 1.91-1.96 (m, 1H).

(e) Synthesis of 5-(methylsulfonyl)-2,3,4,5-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*]oxepine-8-carboxylic acid

The synthesis procedure of Intermediate 8-e was repeated except for using 8-chloro-5-(methylsulfonyl)-2,3,4,5-tetrahydrobenzo[*b*]oxepine-7-carbaldehyde (164.0 mg, 0.57 mmol) to obtain 5-(methylsulfonyl)-2,3,4,5-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*]oxepine-8-carboxylic acid (116.0 mg, 62 %) as a white solid.

LC/MS ESI (+): 341 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.48 (s, 1H), 8.07 (s, 1H), 8.05 (s, 1H), 7.73 (s, 1H), 4.80 (t, 1H, *J*=1.2 Hz), 4.33-4.39 (m, 1H), 3.75-3.80 (m, 1H), 2.89 (s, 3H), 2.50-2.53 (m, 1H) 2.18-2.27 (m, 1H), 2.06-2.14 (m, 1H), 1.75-1.88 (m, 1H)

Intermediate 10) Synthesis of 5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylic acid

(a) Synthesis of 2-ethylhexyl 3-((5-bromo-2-formylphenyl)thio)propanoate

To a solution of 4-bromo-2-fluorobenzaldehyde (3.0 g, 14.78 mmol) in DMF (73.9 ml) were added 2-Ethylhexyl 3-mercaptopropionate (3.7 ml, 16.26 mmol). The reaction mixture was stirred at 40°C for 36 hours. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 2-ethylhexyl 3-((5-bromo-2-formylphenyl)thio)propanoate (4.2 g, 71 %) as a light brown oil.

LC/MS ESI (+): 401 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 10.28 (s, 1H), 7.70 (d, 1H, *J*=8.2Hz), 7.57 (d, 1H, *J*=1.7Hz), 7.46 (dd, 1H, *J*=8.2, 1.7Hz), 4.03-4.05 (m, 2H), 3.24 (t, 2H, *J*=7.4Hz), 2.72 (t, 2H, *J*=7.4Hz), 1.32-1.40 (m, 3H), 1.26-1.30 (m, 6H), 0.90 (t, 6H, *J*=7.4Hz)

(b) Synthesis of 2-ethylhexyl 3-((5-(4,4-diethoxybutyl)-2-(hydroxymethyl)phenyl)thio)propanoate

A solution of 4,4-diethoxybut-1-ene (503.0 mg, 3.49 mmol) in 9-borabicyclo(3.3.1)nonane (7.7 ml, 3.84 mmol) was stirred for 1 hour and concentrated. The residue was dissolved in benzene (7.7 ml)/EtOH (3.9 ml). 2N Na₂CO₃ aqueous solution (35.0 ml, 6.98 mmol) and Pd(PPh₃)₄ (202.0 mg, 0.17 mmol) were added and the reaction mixture at 80°C for 90 minutes. The reaction mixture was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by normal phase column chromatography (EtOAc:*n*-Hex=1:15) to give 2-ethylhexyl 3-((5-(4,4-diethoxybutyl)-2-formylphenyl)thio)propanoate (695.0 mg, 85 %) as crude. To a solution of 2-ethylhexyl 3-((5-(4,4-diethoxybutyl)-2-formylphenyl)thio)propanoate (610.0 mg, 1.31 mmol) in EtOH

(6.5 ml) was added NaBH₄ (64.3 mg, 1.70 mmol). The reaction mixture was stirred for 30 minutes. NH₄Cl was added, and the resulting mixture was stirred for 15 minutes and filtered through celite. The filtrate was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, and concentrated. The residue was purified by normal phase column chromatography (EtOAc:*n*-Hex=1:3) to give 2-ethylhexyl 3-((5-(4,4-diethoxybutyl)-2-(hydroxymethyl)phenyl)thio)propanoate (550.0 mg, 90 %) as a colorless oil.

¹H-NMR (400MHz, CDCl₃): δ 7.31 (d, 1H, *J*=7.7Hz), 7.24 (d, 1H, *J*=1.7Hz), 7.07 (d, 1H, *J*=7.7Hz), 4.74 (d, 2H, *J*=3.3Hz), 4.49 (t, 1H, *J*=5.2Hz), 4.00-4.02 (m, 2H), 3.59-3.67 (m, 2H), 3.44-3.52 (m, 2H), 3.16 (t, 2H, *J*=7.2Hz), 2.61 (t, 4H, *J*=7.1Hz), 2.39 (brs, 1H), 1.65-1.68 (m, 4H), 1.51-1.57 (m, 2H), 1.26-1.37 (m, 2H), 1.26-1.31 (m, 4H), 1.20 (t, 6H, *J*=7.1Hz), 0.89 (t, 6H, *J*=7.1Hz)

(c) Synthesis of 2-ethylhexyl 3-((5-(methylsulfonyl)-3-((2,2,2-trifluoroacetoxy)methyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)propanoate

Sodium methanesulfinate (359.0 mg, 3.52 mmol) was dissolved in TFA (9.8 ml) and the reaction mixture was stirred for 10 minutes. After cooling to 0°C, a solution of 2-ethylhexyl 3-((5-(4,4-diethoxybutyl)-2-(hydroxymethyl)phenyl)thio)propanoate (550.0 mg, 1.17 mmol) in CH₂Cl₂ (1956.0 μl) was added dropwise and the reaction mixture was stirred at 23°C for 1 hour. The reaction mixture was extracted with EtOAc, and the organic extract was washed with sat. NaHCO₃ aqueous solution and brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 3-((5-(methylsulfonyl)-3-((2,2,2-trifluoroacetoxy)methyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)propanoate (217.0 mg, 34 %) as a colorless oil.

¹H-NMR (400MHz, CDCl₃): δ 7.63 (s, 1H), 7.26 (s, 1H), 5.45 (q, 2H, *J*=20.8Hz), 4.28 (t, 1H, *J*=5.1Hz), 4.01-4.04 (m, 2H), 3.20 (t, 2H, *J*=7.5Hz), 2.87-2.93 (m, 1H), 2.76-2.81 (m, 4H), 2.65 (t, 2H, *J*=7.6Hz), 2.47-2.52 (m, 1H), 2.19-2.23 (m, 2H), 1.75-1.86 (m, 1H), 1.56-1.58 (m, 1H), 1.29-1.39 (m, 8H), 0.89 (t, 6H, *J*=7.4Hz)

(d) Synthesis of *tert*-butyl 2-((3-(hydroxymethyl)-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)acetate

To a solution of 2-ethylhexyl 3-((5-(methylsulfonyl)-3-((2,2,2-trifluoroacetoxy)methyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)propanoate (150.0 mg, 0.27 mmol) in DMF (2714.0 μl) was added 1M solution of potassium-*t*-butoxide in THF (543.0 μl, 0.54 mmol) at -60~-50°C. The reaction mixture was stirred for 10 minutes. *tert*-butyl 2-bromoacetate (42.1 μl, 0.29 mmol) was added at -60~-50°C and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain *tert*-butyl 2-((3-(hydroxymethyl)-5-(methylsulfonyl)-5,6,7,8-

tetrahydronaphthalen-2-yl)thio)acetate (67.0 mg, 64 %) as a white amorphous.

¹H-NMR (400MHz, CDCl₃): δ 7.60 (s, 1H), 7.26 (s, 1H), 4.77 (q, 2H, *J*=32.7Hz), 4.27 (t, 1H, *J*=5.9Hz), 3.60 (s, 2H), 2.83-2.89 (m, 1H), 2.71-2.79 (m, 4H), 2.49-2.55 (m, 1H), 2.15-2.20 (m, 2H), 1.73-1.46 (m, 1H), 1.40 (s, 9H)

(e) Synthesis of *tert*-butyl 2-((3-formyl-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)acetate

To a solution of *tert*-butyl 2-((3-(hydroxymethyl)-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)acetate (65.0 mg, 0.17 mmol) in CH₂Cl₂ (1682.0 μl) was added Dess-Martin periodinane (107.0 mg, 0.25 mmol). The reaction mixture was stirred at 24°C for 1 hour. The reaction mixture was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to give *tert*-butyl 2-((3-formyl-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)acetate (71.0 mg, 110 %) as crude. The crude was used the next step without purification.

¹H-NMR (400MHz, CDCl₃): δ 10.23 (s, 1H), 8.04 (s, 1H), 7.29 (s, 1H), 4.31-4.34 (m, 1H), 3.63 (s, 2H), 2.92-2.99 (m, 1H), 2.80-2.87 (m, 4H), 2.52-2.57 (m, 1H), 2.22-2.25 (m, 2H), 1.77-1.82 (m, 1H), 1.44 (s, 9H)

(f) Synthesis of *tert*-butyl 5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylate

To a solution of *tert*-butyl 2-((3-formyl-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalen-2-yl)thio)acetate (67.0 mg, 0.17 mmol) in DMF (1742.0 μl) was added Cs₂CO₃ (85.0 mg, 0.26 mmol). The reaction mixture was stirred at 80°C for 1 hour. The reaction mixture was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to give *tert*-butyl 5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylate (65.0 mg, 102 %) as crude. The crude was used the next step without purification.

¹H-NMR (400MHz, CDCl₃): δ 8.11 (s, 1H), 7.93 (s, 1H), 7.66 (s, 1H), 4.43-4.46 (m, 1H), 3.00-3.08 (m, 1H), 2.90-2.98 (m, 4H), 2.53-2.59 (m, 1H), 2.31-2.35 (m, 1H), 2.17-2.19 (m, 1H), 1.71-1.83 (m, 1H), 1.61 (s, 9H)

(g) Synthesis of 5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylic acid

To a solution of *tert*-butyl 5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylate (65.0 mg, 0.18 mmol) in CH₂Cl₂ (0.5 ml) was added TFA (0.5 ml, 6.53 mmol). The reaction mixture was stirred at 24°C for 30 minutes. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylic acid (30.0 mg, 55 %) as a white amorphous.

LC/MS ESI (-): 309 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.13 (s, 1H), 8.10 (s, 1H), 7.90 (s, 1H), 4.80-4.82 (m, 1H), 3.05 (s, 3H), 2.91-3.02 (m, 2H), 2.48-2.51 (m, 1H), 2.19-2.23 (m, 2H), 1.67-1.72 (m, 1H)

Intermediate 11) Synthesis of 4-methyl-4-(methylsulfonyl)-3,4-dihydro-2H-thieno[3,2-*g*]chromene-7-carboxylic acid

(a) Synthesis of methyl 4-methyl-4-(methylsulfonyl)-3,4-dihydro-2H-thieno[3,2-*g*]chromene-7-carboxylate

To a suspension of methyl 4-(methylsulfonyl)-3,4-dihydro-2H-thieno[3,2-*g*]chromene-7-carboxylate (50.0 mg, 0.15 mmol) in THF (1.0 ml)/CH₃CN (1.0 ml) was added NaH (30.6 mg, 0.77 mmol). After 1 hour, CH₃I (0.1 ml, 1.53 mmol) was added and the reaction mixture was stirred for 3 days. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 4-methyl-4-(methylsulfonyl)-3,4-dihydro-2H-thieno[3,2-*g*]chromene-7-carboxylate (29.0 mg, 56 %) as an off-white amorphous.

LC/MS ESI (+): 341 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.29 (s, 1H), 8.16 (s, 1H), 7.56 (s, 1H), 4.49-4.56 (m, 1H), 4.20-4.26 (m, 1H), 3.88 (s, 3H), 3.00 (s, 3H), 2.61-2.68 (m, 1H), 2.16-2.23 (m, 1H), 1.83 (s, 3H)

(b) Synthesis of 4-methyl-4-(methylsulfonyl)-3,4-dihydro-2H-thieno[3,2-*g*]chromene-7-carboxylic acid

To a suspension of methyl 4-methyl-4-(methylsulfonyl)-3,4-dihydro-2H-thieno[3,2-*g*]chromene-7-carboxylate (27.0 mg, 0.08 mmol) in THF (529.0 μl)/H₂O (264.0 μl) was added LiOH·H₂O (33.3 mg, 0.79 mmol). The reaction mixture was stirred at 60°C for 1 hour. The reaction mixture was concentrated and the residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 4-methyl-4-(methylsulfonyl)-3,4-dihydro-2H-thieno[3,2-*g*]chromene-7-carboxylic acid (20.0 mg, 77 %) as a white amorphous.

LC/MS ESI (-): 325 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.22 (s, 1H), 7.96 (s, 1H), 7.49 (s, 1H), 4.47-4.52 (m, 1H), 4.18-4.22 (m, 1H), 2.97 (s, 3H), 2.59-2.67 (m, 1H), 2.13-2.20 (m, 1H), 1.81 (s, 3H)

Intermediate 12) Synthesis of 5-(methylsulfonyl)-5,8-dihydro-6H-thieno[3,2-*g*]isochromene-2-carboxylic acid

(a) Synthesis of methyl 2-bromo-4-(bromomethyl)benzoate

2-Bromo-4-methylbenzoate (4.6 g, 20.08 mmol) was dissolved in anhydrous 1,2-dichloroethane (60.0 ml), and *N*-bromosuccinimide (4.3 g, 24.10 mmol) and AIBN (0.3 g, 2.01 mmol) were added at room temperature. The mixture was refluxed at 90°C for 1 hour, followed by cooling to room temperature and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under a reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 2-bromo-4-(bromomethyl)benzoate (3.0 g, 48%) as a colorless liquid.

LC/MS ESI (+): 309 (M+1)

¹H-NMR(400MHz, CDCl₃): δ 7.78 (d, 1H, *J*=8.0Hz), 7.69 (d, 1H, *J*=1.6Hz), 7.38 (dd, 1H, *J*=8.0, 1.6Hz), 4.42 (s, 2H), 3.94 (s, 3H)

(b) Synthesis of methyl 2-bromo-4-((2,2-diethoxyethoxy)methyl)benzoate

Glycolaldehyde diethyl acetal (1.6 ml, 12.14 mmol) was dissolved in anhydrous THF (50.0 ml), and NaH (0.5 g, 13.25 mmol) was added at 0°C. The mixture was stirred at 0°C for 30 minutes. Methyl 2-bromo-4-(bromomethyl)benzoate (3.4 g, 11.04 mmol) in THF (50.0 ml) was added at 0 °C. The mixture was stirred at 0°C for 3 hours and extracted with EtOAc. The organic extract was washed with water, dried over anhydrous Na₂SO₄, and concentrated under a reduced pressure. The residue was purified by flash column chromatography (silica gel, *n*-Hex : EtOAc = 9 : 1) to obtain methyl 2-bromo-4-((2,2-diethoxyethoxy)methyl)benzoate (1.7 g, 42%) as a colorless liquid.

¹H-NMR(400MHz, CDCl₃): δ 7.78 (d, 1H, *J*=8.0Hz), 7.66 (d, 1H, *J*=1.2Hz), 7.31-7.34 (m, 1H), 4.67 (t, 1H, *J*=10.4, 5.2Hz), 4.59 (s, 2H), 3.93 (s, 3H), 3.68-3.75 (m, 2H), 3.53-3.62 (m, 4H), 1.23 (t, 6H, *J*=14.0, 6.8Hz)

(c) Synthesis of 4-((2,2-diethoxyethoxy)methyl)-2-(methylthio)benzoic acid

Methyl 2-bromo-4-((2,2-diethoxyethoxy)methyl)benzoate (480.0 mg, 1.33 mmol) was dissolved in DMF (4.0 ml), and sodium methanethiolate (466 mg, 6.64 mmol) was added at room temperature. The mixture was stirred at 80°C for 15 hours, followed by cooling to room temperature and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under a reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 4-((2,2-diethoxyethoxy)methyl)-2-(methylthio)benzoic acid (380.0 mg, 91%) as a colorless liquid

LC/MS ESI (-): 313 (M-1)

¹H-NMR(400MHz, CDCl₃): δ 8.10 (d, 1H, *J*=8.0Hz), 7.30 (s, 1H), 7.14 (dd, 1H, *J*=8.0, 0.8Hz), 4.70 (t, 1H, *J*=10.4, 5.2Hz), 4.65 (s, 2H), 3.68-3.76 (m, 2H), 3.55-3.63 (m, 4H), 2.48 (s, 3H), 1.24 (t, 6H, *J*=14.0, 6.8Hz)

(d) Synthesis of 4-((2,2-diethoxyethoxy)methyl)-2-(methylthio)phenyl)methanol

4-((2,2-diethoxyethoxy)methyl)-2-(methylthio)benzoic acid (380.0 mg, 1.21 mmol) was dissolved in THF (12.0 ml), and 1.0M solution of LiAlH₄ in THF (1.2 ml, 1.20 mmol) was added at room temperature. The mixture was stirred at room temperature for 1 hour and H₂O was added at 0°C. The reaction mixture was filtered through Celite and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under a reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 4-((2,2-diethoxyethoxy)methyl)-2-(methylthio)phenylmethanol (280.0 mg, 77%) as a colorless liquid.

¹H-NMR(400MHz, CDCl₃): δ 7.34 (d, 1H, *J*=8.0Hz), 7.26 (m, 1H), 7.12-7.14 (m, 1H), 4.75 (brs, 2H), 4.66 (t, 1H, *J*=10.4, 5.2Hz), 4.58 (s, 2H), 3.66-3.74 (m, 2H), 3.51-3.61 (m, 4H), 2.50 (s, 3H), 2.08 (brs, 1H), 1.22 (t, 6H, *J*=14.0, 7.2Hz)

(e) Synthesis of 4-(methylsulfonyl)-7-(methylthio)isochroman-6-yl)methanol

Sodium methanesulfinate (285.0 mg, 2.80 mmol) was dissolved in TFA (7.5 ml) and stirred at room temperature for 30 minutes. 4-((2,2-diethoxyethoxy)methyl)-2-(methylthio)phenylmethanol (280.0 mg, 0.93 mmol) in CH₂Cl₂ (1.5 ml) was slowly added at room temperature. The mixture was stirred at room temperature for 30 minutes and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under a reduced pressure. The mixture was dissolved in THF (4.0 ml)/MeOH (1.0 ml)/H₂O (1.0 ml) and LiOH·H₂O (223.0 mg, 932.00 mmol) was added at room temperature. The mixture was stirred at room temperature for 30 minutes and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to obtain 4-(methylsulfonyl)-7-(methylthio)isochroman-6-yl)methanol (208.0 mg, 77%) as a colorless liquid.

LC/MS ESI (-): 287 (M-1)

¹H-NMR(400MHz, CDCl₃): δ 7.66 (s, 1H), 6.91 (s, 1H), 4.86-4.91 (m, 2H), 4.70-4.80 (m, 3H), 3.97-4.01 (m, 1H), 3.87-3.88 (m, 1H), 2.67 (s, 3H), 2.50 (s, 3H)

(f) Synthesis of 4-(methylsulfonyl)-7-(methylthio)isochromane-6-carbaldehyde

4-(Methylsulfonyl)-7-(methylthio)isochroman-6-yl)methanol (208.0 mg, 0.72 mmol) was dissolved in CH₂Cl₂ (7.0 ml) and Dess-Martin Periodinane (398.0 mg, 0.94 mmol) was added at room temperature. The mixture was stirred at room temperature for 30 minutes and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under a reduced pressure. The residue was purified by flash column chromatography (silica gel, *n*-Hex : EtOAc = 1 : 1) to obtain 4-(methylsulfonyl)-7-(methylthio)isochromane-6-carbaldehyde (150.0 mg, 72%) as a colorless liquid.

LC/MS ESI (+): 287 (M+1)

¹H-NMR(400MHz, CDCl₃): δ 10.16 (s, 1H), 8.10 (s, 1H), 7.00 (s, 1H), 4.93-4.97

(m, 2H), 4.80-4.84 (m, 1H), 4.02-4.06 (m, 1H), 3.94-3.95 (m, 1H), 2.69 (s, 3H), 2.48 (s, 3H)

(g) Synthesis of 5-(methylsulfonyl)-5,8-dihydro-6*H*-thieno[3,2-*g*]isochromene-2-carboxylic acid

A mixture of 4-(Methylsulfonyl)-7-(methylthio)isochroman-6-carbaldehyde (150.0 mg, 0.52 mmol), magnesium oxide (21.1 mg, 0.52 mmol) and 2-chloroacetic acid (990.0 mg, 10.48 mmol) was stirred at 110°C for 16 hours and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under a reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 5-(methylsulfonyl)-5,8-dihydro-6*H*-thieno[3,2-*g*]isochromene-2-carboxylic acid (50.0 mg, 30%) as a white solid.

LC/MS ESI (-): 311 (M-1)

¹H-NMR(400MHz, CDCl₃): δ 8.26 (s, 1H), 8.14 (s, 1H), 7.64 (s, 1H), 4.91-5.08 (m, 3H), 4.07-4.11 (m, 2H), 2.66 (s, 3H)

Intermediate 13) Synthesis of 4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

(a) Synthesis of 7-chloro-4-fluoro-6-methyl-4-(methylsulfonyl)chromane

7-chloro-6-methyl-4-(methylsulfonyl)chromane (850.0 mg, 3.26 mmol) was dissolved in THF (30.0 mL), and LDA (2.6 mL, 3.91 mmol) was slowly added at -78°C and stirred for 0.5 hour. NFS (2.3 g, 7.17 mmol) was added, followed by stirring at -78°C for 3 hours. The reaction was quenched with H₂O, and the reaction mixture was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under a reduced pressure. The residue was purified by flash column chromatography (silica gel, *n*-Hex : EtOAc = 85 : 15) to obtain 7-chloro-4-fluoro-6-methyl-4-(methylsulfonyl)chromane (600.0 mg, 66%) as a white solid

¹H-NMR (400MHz, DMSO-*d*₆): δ 7.53 (s, 1H), 6.97 (s, 1H), 4.59-4.65 (m, 1H), 4.28-4.35 (m, 1H), 3.05 (s, 3H), 2.72-2.80 (m, 1H), 2.49-2.56 (m, 1H), 2.33 (s, 3H)

(b) Synthesis of 6-(bromomethyl)-7-chloro-4-fluoro-4-(methylsulfonyl)chromane

The synthesis procedure of Intermediate 8-c was repeated except for using 7-chloro-4-fluoro-6-methyl-4-(methylsulfonyl)chromane (500.0 mg, 1.79 mmol) to obtain 6-(bromomethyl)-7-chloro-4-fluoro-4-(methylsulfonyl)chromane (520.0 mg, 81%).

¹H-NMR (400MHz, DMSO-*d*₆): δ 7.75 (s, 1H), 7.01 (s, 1H), 4.67-4.68 (m, 1H), 4.56 (q, 2H, *J*=10.4, 21.1Hz), 4.35-4.41 (m, 1H), 3.06 (s, 3H), 2.74-2.82 (m, 1H), 2.49-2.60 (m, 1H)

(c) Synthesis of 6-(bromomethyl)-7-chloro-4-fluoro-4-(methylsulfonyl)chromane

The synthesis procedure of Intermediate 8-d was repeated except for using 6-(bromomethyl)-7-chloro-4-fluoro-4-(methylsulfonyl)chromane (400.0 mg, 1.11 mmol) to obtain 7-chloro-4-fluoro-4-(methylsulfonyl)chromane-6-carbaldehyde (225.0 mg, 68%).

LC/MS ESI (+): 293 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 10.32 (s, 1H), 8.20 (s, 1H), 7.04 (s, 1H), 4.73-4.80 (m, 1H), 4.49-4.55 (m, 1H), 3.09 (s, 3H), 2.86-2.93 (m, 1H), 2.47-2.59 (m, 1H)

(d) Synthesis of 4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

7-chloro-4-fluoro-4-(methylsulfonyl)chromane-6-carbaldehyde (210.0 mg, 0.71 mmol) was dissolved in anhydrous DMF (7.1 mL), and methyl 2-mercaptoacetate (114.0 mg, 1.07 mmol) and Cs₂CO₃ (514.0 mg, 1.57 mmol) were added, followed by heating at 80°C for 2 hours. The reaction mixture was cooled to room temperature and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid (72.0 mg, 30%) as a yellow solid

LC/MS ESI (-): 329 (M-1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.47 (s, 1H), 8.32 (s, 1H), 8.13 (s, 1H), 7.66 (s, 1H), 4.53-4.56 (m, 1H), 4.40-4.44 (m, 2H), 2.95-2.97 (m, 2H), 2.64-2.67 (m, 2H)

Intermediate 14) Synthesis of 8,8-difluoro-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylic acid

(a) Synthesis of 7-chloro-6-methyl-4-(methylsulfonyl)-3,4-dihydronaphthalen-1(2*H*)-one

To a solution of 6-chloro-7-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalene (700.0 mg, 2.71 mmol) in acetic anhydride (5114.0 μl, 54.10 mmol) was added chromium oxide(VI) (812.0 mg, 8.12 mmol) at 0°C. The reaction mixture was stirred at 0°C for 2 hours. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 7-chloro-6-methyl-4-(methylsulfonyl)-3,4-dihydronaphthalen-1(2*H*)-one (430.0 mg, 58 %) as a white amorphous.

LC/MS ESI (+): 273 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 8.12 (s, 1H), 7.40 (s, 1H), 4.31-4.33 (m, 1H), 3.16-3.26 (m, 1H), 2.93 (s, 3H), 2.86-2.91 (m, 1H), 2.64-2.71 (m, 1H), 2.51-2.60 (m, 1H), 2.47 (s, 3H)

(b) Synthesis of 7-chloro-1,1-difluoro-6-methyl-4-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalene

A suspension of 7-chloro-6-methyl-4-(methylsulfonyl)-3,4-dihydronaphthalen-1(2H)-one (430.0 mg, 1.58 mmol) in DAST (2.0 ml, 15.14 mmol) was stirred at 65°C overnight. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 7-chloro-1,1-difluoro-6-methyl-4-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalene (186.0 mg, 40 %) as a white amorphous.

LC/MS ESI (-): 293 (M-1)

¹H-NMR (400MHz, CDCl₃): δ 7.77 (s, 1H), 7.60 (s, 1H), 4.22-4.26 (m, 1H), 2.77 (s, 3H), 2.65-2.73 (m, 1H), 2.51-2.62 (m, 2H), 2.43 (s, 3H), 2.23-2.35 (m, 1H)

(c) Synthesis of 6-(bromomethyl)-7-chloro-1,1-difluoro-4-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalene

To a solution of 7-chloro-1,1-difluoro-6-methyl-4-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalene (150.0 mg, 0.51 mmol) and N-bromosuccinimide (109.0 mg, 0.61 mmol) in 1,2-dichloroethane (2545.0 μl) was added AIBN (8.4 mg, 0.05 mmol). The reaction mixture was stirred at 80°C for 1 hour. The reaction mixture was purified by flash column chromatography (silica gel, *n*-Hex : EtOAc = 5 : 1) to obtain 6-(bromomethyl)-7-chloro-1,1-difluoro-4-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalene (105.0 mg, 55 %) as a white amorphous.

LC/MS ESI (-): 371 (M-1)

¹H-NMR (400MHz, CDCl₃): δ 7.85 (s, 2H), 4.55-4.64 (m, 2H), 4.25-4.29 (m, 1H), 2.82 (s, 3H), 2.68-2.73 (m, 1H), 2.56-2.59 (m, 2H), 2.27-2.34 (m, 1H)

(d) Synthesis of 3-chloro-5,5-difluoro-8-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalene-2-carbaldehyde

A suspension of 6-(bromomethyl)-7-chloro-1,1-difluoro-4-(methylsulfonyl)-1,2,3,4-tetrahydronaphthalene (105.0 mg, 0.28 mmol), *N*-methyl morpholine-*N*-oxide (49.4 mg, 0.42 mmol) and molecular sieve (4Å) in CH₃CN (2.8 ml) was stirred at 25°C for 1 hour. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 3-chloro-5,5-difluoro-8-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalene-2-carbaldehyde (60.0 mg, 69 %) as a light brown amorphous.

LC/MS ESI (-): 307 (M-1)

¹H-NMR (400MHz, CDCl₃): δ 10.49 (s, 1H), 8.15 (s, 1H), 7.92 (s, 1H), 4.30-4.33 (m, 1H), 2.92 (s, 3H), 2.83-2.87 (m, 1H), 2.68-2.75 (m, 1H), 2.47-2.57 (m, 1H), 2.34-2.39 (m, 1H)

(e) Synthesis of 8,8-difluoro-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-

b]thiophene-2-carboxylic acid

To a solution of 3-chloro-5,5-difluoro-8-(methylsulfonyl)-5,6,7,8-tetrahydronaphthalene-2-carbaldehyde (58.0 mg, 0.19 mmol) and Cs₂CO₃ (122.0 mg, 0.38 mmol) in DMF (939.0 μ l) was added methyl thioglycollate (18.5 μ l, 0.21 mmol). The reaction mixture was stirred at 80°C for 1 hour. The reaction mixture was cooled to 60°C and LiOH·H₂O (79.0 mg, 1.88 mmol) was added and stirred for 1 hour. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 8,8-difluoro-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxylic acid (33.0 mg, 51 %) as an off-white amorphous.

LC/MS ESI (-): 345 (M-1)

¹H-NMR (400MHz, DMS-*d*₆): δ 8.48 (s, 1H), 8.18 (s, 1H), 8.13 (s, 1H), 4.89-4.90 (m, 1H), 3.17 (s, 3H), 2.66-2.73 (m, 2H), 2.32-2.42 (m, 2H)

Intermediate 15) Synthesis of 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

(a) Synthesis of 3-(3-chloro-4-methylphenoxy)propanoic acid

To a solution of 2-chloro-4-(3,3-diethoxypropoxy)-1-methylbenzene (3.0 g, 11.00 mmol) in THF (27.5 ml)/H₂O (27.5 ml) was added Oxone (10.1 g, 33.00 mmol). The reaction mixture was stirred at 25°C overnight and filtered. The filtrate was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated to give 3-(3-chloro-4-methylphenoxy)propanoic acid (2.4 g, 100 %) as a white amorphous.

LC/MS ESI (-): 213 (M-1)

¹H-NMR (400MHz, CDCl₃): δ 7.11 (d, 1H, *J*=8.4Hz), 6.92 (d, 1H, *J*=2.5Hz), 6.73 (dd, 1H, *J*=8.4, 2.4Hz), 4.21 (t, 2H, *J*=6.2Hz), 2.84 (t, 2H, *J*=6.2Hz), 2.29 (s, 3H)

(b) Synthesis of 7-chloro-6-methylchroman-4-one

3-(3-chloro-4-methylphenoxy)propanoic acid (2.4 g, 10.95 mmol) was dissolved in trifluoromethanesulfonic acid (4.8 ml, 54.70 mmol) and the reaction mixture was stirred for 2.5 hours. Ice chip was added slowly and the resulting mixture was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain 7-chloro-6-methylchroman-4-one (795.0 mg, 37 %) as a white amorphous.

LC/MS ESI (+): 197 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.74 (s, 1H), 7.01 (s, 1H), 4.52 (t, 2H, *J*=6.5Hz), 2.84 (t, 2H, *J*=6.5Hz), 2.32 (s, 3H)

(c) Synthesis of 6-(bromomethyl)-7-chlorochroman-4-one

The synthesis procedure of Intermediate 8-c was repeated except for using 7-chloro-6-methylchroman-4-one (950.0 mg, 4.83 mmol) to obtain 6-(bromomethyl)-7-chlorochroman-4-one (1.4 g, 87 %) as an ivory solid.

LC/MS ESI (+): 275 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.97 (s, 1H), 7.10 (s, 1H), 4.54-4.58 (m, 4H), 2.82 (t, 2H, J=6.5Hz)

(d) Synthesis of 7-chloro-4-oxochromane-6-carbaldehyde

The synthesis procedure of Intermediate 8-d was repeated except for using 6-(bromomethyl)-7-chlorochroman-4-one (1.3 g, 4.72 mmol) to obtain 7-chloro-4-oxochromane-6-carbaldehyde (660.0 mg, 66%) as a white solid.

LC/MS ESI (+): 211 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 10.34 (s, 1H), 8.50 (s, 1H), 7.10 (s, 1H), 4.64 (t, 2H, J=6.5Hz), 2.87 (t, 2H, J=6.5Hz)

(e) Synthesis of methyl 4-oxo-3,4-dihydro-2H-thieno[3,2-g]chromene-7-carboxylate

The synthesis procedure of Intermediate 8-d was repeated except for using 7-chloro-4-oxochromane-6-carbaldehyde (660.0 mg, 3.13 mmol) to obtain 4-oxo-3,4-dihydro-2H-thieno[3,2-g]chromene-7-carboxylate (580.0 mg, 71%) as an off white solid.

LC/MS ESI (+): 263 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 8.49 (s, 1H), 8.26 (s, 1H), 7.74 (s, 1H), 4.59 (t, 2H, J=6.4Hz), 3.87 (s, 3H), 2.87 (t, 2H, J=6.4Hz)

(f) Synthesis of methyl 4-hydroxy-3,4-dihydro-2H-thieno[3,2-g]chromene-7-carboxylate

To a solution of methyl 4-oxo-3,4-dihydro-2H-thieno[3,2-g]chromene-7-carboxylate (810.0 mg, 3.09 mmol) in EtOH (15.0 ml) was added NaBH₄ (140.0 mg, 3.71 mmol). The reaction mixture was stirred at 26°C for 2 hours. H₂O was added and insoluble white solid was filtered to give methyl 4-hydroxy-3,4-dihydro-2H-thieno[3,2-g]chromene-7-carboxylate (665.0 mg, 81%) as a white solid.

LC/MS ESI (+): 265 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.11 (s, 1H), 7.79 (s, 1H), 7.40 (s, 1H), 5.55 (m, 1H), 4.75-4.79 (m, 1H), 4.23-4.33 (m, 2H), 3.85 (s, 3H), 2.02-2.09 (m, 1H), 1.88-1.94 (m, 1H)

(g) Synthesis of methyl 4-chloro-3,4-dihydro-2H-thieno[3,2-g]chromene-7-carboxylate

To a solution of methyl 4-hydroxy-3,4-dihydro-2H-thieno[3,2-g]chromene-7-

carboxylate (200.0 mg, 0.76 mmol) in toluene (3784.0 μ l) was added SOCl₂ (110.0 μ l, 1.51 mmol). The reaction mixture was stirred at 60°C for 2 hours. After cooling, the reaction mixture was concentrated to give methyl 4-chloro-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (210.0 mg, 98%) as a white amorphous without purification.

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.13 (s, 1H), 8.02 (s, 1H), 7.51 (s, 1H), 5.72 (t, 1H, *J*=3.4Hz), 4.36-4.46 (m, 2H), 3.86 (s, 3H), 2.42-2.48 (m, 1H), 2.26-2.31 (m, 1H)

(h) Synthesis of methyl 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate

A solution of methyl 4-chloro-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (80.0 mg, 0.28 mmol), pyrazole (57.8 mg, 0.85 mmol) and K₂CO₃ (117.0 mg, 0.85 mmol) in DMA (2829.0 μ l) was stirred at 60°C for 1hour and then stirred at 80°C. After 1hour, the reaction mixture was stirred at 100°C for 1hour. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (26.0 mg, 29 %) as a white amorphous.

LC/MS ESI (+): 315 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.87 (s, 1H), 7.61 (d, 1H, *J*=1.5Hz), 7.51 (s, 1H), 7.37 (s, 1H), 7.22 (d, 1H, *J*=2.1Hz), 6.25-6.26 (m, 1H), 5.72 (t, 1H, *J*=5.1Hz), 4.31-4.37 (m, 1H), 4.15-4.21 (m, 1H), 3.92 (s, 3H), 2.56-2.64 (m, 1H), 2.40-2.48 (m, 1H)

(i) Synthesis of 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

To a suspension of methyl 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (25.0 mg, 0.08 mmol) in THF (530.0 μ l)/H₂O (265.0 μ l) was added LiOH·H₂O (33.4 mg, 0.78 mmol). The reaction mixture was stirred at 60°C for 1hour. The reaction mixture was cooled to room temperature. 1*N*-HCl was added and insoluble white solid was filtered to give 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid (17.0 mg, 71%) as a white solid.

LC/MS ESI (-): 299 (M-1)

Intermediate 16) Synthesis of 4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

To a solution of 2-Pyrrolidinone (64.5 μ l, 0.85 mmol) in DMA (4.2 ml) was added NaH (33.9 mg, 0.85 mmol). The reaction mixture was stirred at 100°C for 30 minutes. methyl 4-chloro-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (120.0 mg, 0.42 mmol) was added and stirred for 1hour. The reaction mixture was cooled to 80°C. LiOH·H₂O (53.4 mg, 1.27 mmol) was added and stirred for 1hour. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid

in CH₃CN: 0.1% formic acid in H₂O) to obtain 4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid (13.0 mg, 10 %) as a white amorphous.

LC/MS ESI (+): 318 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 7.93 (s, 1H), 7.57 (s, 1H), 7.42 (s, 1H), 5.41-5.45 (m, 1H), 4.27-4.40 (m, 2H), 3.23-3.32 (m, 1H), 2.95-3.01 (m, 1H), 2.36-2.43 (m, 2H), 2.10-2.19 (m, 1H), 1.90-2.01 (m, 3H)

Intermediate 17) Synthesis of 4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

(a) Synthesis of methyl 4-bromo-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate

Methyl 4-hydroxy-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (210.0 mg, 0.79 mmol) was dissolved in CH₂Cl₂ (3.9 mL), and PBr₃ (323.0 mg, 1.19 mmol) was added. After stirring at room temperature for 2 hours, and the reaction mixture was concentrated under a reduced pressure to obtain crude solid compound of methyl 4-bromo-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (250.0 mg, 95%).

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.18 (s, 1H), 8.07 (s, 1H), 7.54 (s, 1H), 6.05-6.06 (m, 1H), 4.54-4.57 (m, 2H), 3.92 (s, 3H), 2.39-2.45 (m, 2H)

(b) Synthesis of methyl 4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate

Methyl 4-bromo-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (300.0 mg, 0.91 mmol) was dissolved in DMA (9.1 mL), and NaCN (90.0 mg, 1.83 mmol) was added at room temperature. The mixture was stirred at 60°C for 2 hours, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated under a reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN: 0.1% formic acid in H₂O) to obtain methyl 4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (39.0 mg, 15%) as an off-white solid.

LC/MS ESI (+): 274 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 8.17 (s, 1H), 8.03 (s, 1H), 7.56 (s, 1H), 4.68 (t, 1H, *J*=6.0Hz), 4.31 (t, 2H, *J*=5.2Hz), 3.87 (s, 3H), 2.29-2.39 (m, 2H)

(c) Synthesis of 4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

Methyl 4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (39.0 mg, 0.14 mmol) was dissolved in THF/H₂O (1.5 mL, 3/1 v/v), and LiOH·H₂O (17.9 mg, 0.43 mmol) was added. After stirring at room temperature for 15 hours, the reaction mixture was concentrated under a reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in

H₂O) to obtain methyl 4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (17.0 mg, 46%) as a white solid.

LC/MS ESI (+): 260 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 13.3 (br, 1H), 7.96 (s, 1H), 7.91 (s, 1H), 7.44 (s, 1H), 4.60 (t, 1H, *J*=6.0Hz), 4.22 (t, 2H, *J*=5.2 Hz), 2.20-2.26 (m, 2H)

Intermediate 18) Synthesis of 4-azido-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

(a) Synthesis of methyl 4-azido-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate

Methyl 4-bromo-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (95.0 mg, 0.29 mmol) was dissolved in DMA (2.9 mL), The mixture was stirred at 60°C for 3 hours, and extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, and concentrated under a reduced pressure. The residue was purified by flash column chromatography (silica gel, *n*-Hex : EtOAc = 6 : 1) to obtain methyl 4-azido-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (50.0 mg, 60%) as a white solid.

LC/MS ESI (+): 290 (M+1)

¹H-NMR (400MHz, CDCl₃): δ 7.97 (s, 1H), 7.72 (s, 1H), 7.32 (s, 1H), 4.77 (t, 1H, *J*=4.1 Hz), 4.31-4.35 (m, 2H), 3.93 (s, 3H), 2.10-2.23 (m, 2H)

(b) Synthesis of 4-azido-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid

Methyl 4-azido-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylate (15.0 mg, 0.05 mmol) was dissolved in THF/H₂O (0.5 mL, 3/1 v/v), and LiOH·H₂O (21.7 mg, 0.52 mmol) was added. The reaction mixture was stirred at 60°C for 15 hours, 1*N* HCl (3.0 mL) was added, and extracted with CH₂Cl₂. The organic extract was washed with brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure to obtain 4-azido-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid (10.0 mg, 70%) as an off-white solid.

LC/MS ESI (-): 274 (M-1)

Example 1) Synthesis of *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide

(a) Synthesis of 2-chloro-6-(4-chlorophenoxy)pyridin-4-amine

2,6-Dichloropyridine-4-amine (3.0 g, 18.40 mmol) and 4-chlorophenol (4.7 g, 36.80 mmol) were dissolved in sulfolane (96.0 mL) and K₂CO₃ (5.1 g, 36.80 mmol) was added. The reaction mixture was stirred at 160°C for 24 hours, cooled to room temperature, H₂O was added, and extracted with EtOAc. The organic extract was washed

with 1N NaOH aqueous solution and brine, dried over anhydrous Na₂SO₄ and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain 2-chloro-6-(4-chlorophenoxy)pyridin-4-amine (2.5 g, 53%) as a white solid.

LC/MS ESI (+): 255 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 7.45 (d, 2H, *J*=8.8Hz), 7.12 (d, 2H, *J*=8.8Hz), 6.55 (brs, 2H), 6.31 (d, 1H, *J*=1.6Hz), 5.93 (d, 1H, *J*=1.6Hz)

(b) Synthesis of *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide
1-(Methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxylic acid (190.0 mg, 0.61 mmol) was dissolved in CH₂Cl₂ (6.1 mL), and DMF (1.2 μL, 0.01 mmol) and (COCl)₂ (51.6 μL, 0.61 mmol) were added. The reaction mixture was stirred at 25°C for 2 hours and concentrated under reduced pressure to obtain 1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carbonyl chloride. To the residue, 2-chloro-6-(4-chlorophenoxy)pyridin-4-amine (155.0 mg, 0.61 mmol) and 1,4-Dioxane (2.0 mL) were added and the reaction mixture was stirred at 80°C for 15 hours and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide (166.0 mg, 50%) as a white solid.

LC/MS ESI (+): 550 (M+1)

¹H-NMR(400MHz, DMSO-*d*₆): δ 10.87 (brs, 1H), 8.20 (s, 1H), 8.10 (s, 1H), 7.58 (s, 2H), 7.45 (dd, 2H, *J*=8.8, 2.1Hz), 7.22 (s, 1H), 7.18 (dd, 2H, *J*=8.8, 2.1Hz), 4.29 (t, 2H, *J*=4.9Hz), 3.82 (t, 2H, *J*=4.6Hz), 3.11 (s, 3H)

Compounds from **Examples 2 to 14** were synthesized through the synthesis route of Example 1, and data of these compounds are listed as follows.

[Table 2]

Ex.	Compound	Analysis data
2	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1 <i>H</i> -thieno[3',2':4,5]benzo[1,2- <i>b</i>][1,4]oxazine-7-carboxamide	LC/MS ESI (+): 578 (M+1) ¹ H-NMR(400MHz, DMSO- <i>d</i> ₆): δ 10.94 (s, 1H), 8.28 (s, 1H), 8.18 (s, 1H), 7.67 (s, 1H), 7.58 (s, 1H), 7.53 (d, 2H, <i>J</i> =8.8Hz), 7.31 (s, 1H), 7.25 (d, 2H, <i>J</i> =8.8Hz), 3.68 (s, 2H), 3.38 (s, 3H), 1.36 (s, 6H)

3	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2- <i>b</i>][1,4]oxazepine-8-carboxamide	LC/MS ESI (+): 564 (M+1) ¹ H-NMR(400MHz, DMSO- <i>d</i> ₆): δ 11.10 (s, 1H), 8.36 (s, 1H), 8.08 (s, 1H), 7.90 (s, 1H), 7.70 (d, 1H, <i>J</i> =1.2Hz), 7.55 (d, 2H, <i>J</i> =8.8Hz), 7.33 (s, 1H, <i>J</i> =1.2Hz), 7.29 (d, 2H, <i>J</i> =8.8Hz), 4.15-4.17 (m, 2H), 3.75-3.77 (m, 2H), 3.11 (s, 3H), 2.08-2.10 (m, 2H)
4	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3- <i>g</i>]quinoline-2-carboxamide	LC/MS ESI (+): 576 (M+1) ¹ H-NMR(400MHz, DMSO- <i>d</i> ₆): δ 10.98 (s, 1H), 8.30 (s, 1H), 8.21 (s, 1H), 8.14 (s, 1H), 7.67 (s, 1H), 7.53 (d, 2H, <i>J</i> =8.7Hz), 7.32 (s, 1H), 7.26 (d, 2H, <i>J</i> =8.7Hz), 3.79 (t, 2H, <i>J</i> =5.7Hz), 3.12 (s, 3H), 1.85 (t, 2H, <i>J</i> =5.7Hz), 1.37 (s, 6H)
5	<i>tert</i> -butyl 7-((2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)carbamoyl)-1-(methylsulfonyl)-2,3-dihydrothieno[2,3- <i>g</i>]quinoxaline-4(1 <i>H</i>)-carboxylate	LC/MS ESI (+): 679 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.93 (brs, 1H), 8.35 (s, 1H), 8.24 (s, 1H), 8.03 (d, 1H, <i>J</i> =8.7Hz), 7.60 (d, 1H, <i>J</i> =1.3Hz), 7.47 (d, 2H, <i>J</i> =8.8Hz), 7.24 (d, 1H, <i>J</i> =1.3 Hz), 7.19 (d, 2H, <i>J</i> =8.8Hz), 3.82-3.84 (m, 2H), 3.79-3.80 (m, 2H), 3.05 (s, 3H), 1.43 (s, 9H)
6	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3- <i>g</i>]quinoline-2-carboxamide	LC/MS ESI (+): 548 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.98 (s, 1H), 8.32 (s, 1H), 8.13 (s, 1H), 7.90 (s, 1H), 7.66 (s, 1H), 7.53 (d, 2H, <i>J</i> =8.8Hz), 7.28 (s, 1H), 7.26 (d, 2H, <i>J</i> =8.8Hz), 3.75 (t, 2H, <i>J</i> =6.3Hz), 3.06 (s, 3H), 2.93 (t, 2H, <i>J</i> =6.5Hz), 1.95-1.99 (m, 2H)
7	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3- <i>g</i>]quinoxaline-7-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.81 (brs, 1H), 8.20 (s, 1H), 7.89 (s, 1H), 7.67 (s, 1H), 7.55 (d, 2H, <i>J</i> =8.7Hz), 7.33 (s, 1H), 7.32 (s, 1H), 7.28 (d, 2H, <i>J</i> =8.7Hz), 3.79 (t, 2H, <i>J</i> =5.3Hz), 3.53 (t, 2H, <i>J</i> =5.3Hz), 3.04 (d, 6H, <i>J</i> =2.6Hz)
8	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 549 (M+1). ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.94 (s, 1H), 8.31 (s, 1H), 8.08 (s, 1H), 7.67 (d, 1H, <i>J</i> =1.1Hz), 7.59 (s, 1H), 7.53 (d, 2H, <i>J</i> =8.9Hz), 7.31 (d, 1H, <i>J</i> =1.1Hz), 7.27 (d, 2H, <i>J</i> =8.9Hz), 4.82 (m, 1H), 4.46-4.53 (m, 1H), 4.31-4.36 (m, 1H), 3.18 (s, 3H), 2.53-2.69 (m, 1H), 2.29-2.40 (m, 1H).

9	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-2,3,4,5-tetrahydrothieno[3',2':4,5]benzo[1,2- <i>b</i>]oxepine-8-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.90 (s, 1H), 8.28 (s, 1H), 8.03 (s, 1H), 7.69 (s, 1H), 7.59 (d, 1H, <i>J</i> =1.4Hz), 7.44-7.48 (m, 2H), 7.25 (s, 1H), 7.17-7.21 (m, 2H), 4.78 (t, 1H, <i>J</i> =5.4Hz), 4.29-4.34 (m, 1H), 3.68-3.73 (m, 1H), 2.81 (s, 3H), 2.25-2.50 (m, 1H), 2.16-2.19 (m, 1H), 2.04-2.04 (m, 1H), 1.70-1.74 (m, 1H)
10	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3- <i>b</i>]thiophene-2-carboxamide	LC/MS ESI (+): 547 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 11.0 (s, 1H), 8.35 (s, 1H), 8.12 (s, 1H), 7.91 (s, 1H), 7.66 (d, 1H, <i>J</i> =1.3Hz), 7.53 (d, 2H, <i>J</i> =8.9Hz), 7.31 (d, 1H, <i>J</i> =1.3Hz), 7.26 (d, 2H, <i>J</i> =8.9Hz), 4.76-4.79 (m, 1H), 3.01 (s, 3H), 2.82-2.94 (m, 2H), 2.43-2.46 (m, 1H), 2.14-2.20 (m, 2H), 1.62-1.66 (m, 1H)
11	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.94 (brs, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 7.65 (s, 1H), 7.57 (s, 1H), 7.52 (d, 2H, <i>J</i> =8.5Hz), 7.30 (s, 1H), 7.25 (d, 2H, <i>J</i> =8.3Hz), 4.49-4.54 (m, 1H), 4.20-4.24 (m, 1H), 2.98 (s, 3H), 2.62 (m, 1H), 2.15-2.22 (m, 1H), 1.84 (s, 3H)
12	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,8-dihydro-6 <i>H</i> -thieno[3,2- <i>g</i>]isochromene-2-carboxamide	LC/MS ESI (+): 549 (M+1) ¹ H-NMR(400MHz, DMSO- <i>d</i> ₆):δ 10.96 (brs, 1H), 8.32 (s, 1H), 8.09 (s, 1H), 7.87 (s, 1H), 7.60 (d, 1H, <i>J</i> =1.2Hz), 7.45-7.47 (m, 2H), 7.25 (d, 1H, <i>J</i> =0.8Hz), 7.18-7.22 (m, 2H), 4.96 (d, 1H, <i>J</i> =15.6Hz), 4.82 (d, 1H, <i>J</i> =15.6Hz), 4.60 (d, 1H, <i>J</i> =12.8Hz), 4.48 (s, 1H), 4.03 (dd, 1H, <i>J</i> =12.8, 3.6Hz), 2.63 (s, 3H)
13	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 567 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.92 (brs, 1H), 8.27 (s, 1H), 8.24 (s, 1H), 7.64 (s, 1H), 7.58 (s, 1H), 7.46 (d, 2H, <i>J</i> =8.8Hz), 7.21 (s, 1H), 7.18 (d, 2H, <i>J</i> =8.8Hz), 4.46-4.52 (m, 1H), 4.33-4.38 (m, 1H), 2.93 (s, 3H), 2.87-2.93 (m, 1H), 2.60-2.67 (m, 1H)
14	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-8,8-difluoro-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3- <i>b</i>]thiophene-2-carboxamide	LC/MS ESI (-): 581 (M-1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 11.13 (s, 1H), 8.57 (s, 1H), 8.43 (s, 1H), 8.23 (s, 1H), 7.67 (d, 1H, <i>J</i> =1.1Hz), 7.52 (d, 2H, <i>J</i> =8.9Hz),

		7.31 (d, 1H, $J=0.7\text{Hz}$), 7.26 (d, 2H, $J=8.9\text{Hz}$), 4.91 (m, 1H), 3.19 (s, 3H), 2.80-2.90 (m, 1H), 2.70-2.75 (m, 1H), 2.36-2.45 (m, 2H)
--	--	---

Example 15) Synthesis of *N*-(2-chloro-6-(*p*-tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide

5

(a) Synthesis of 2-chloro-6-(*p*-tolylloxy)pyridin-4-amine

To a solution of 2,6-dichloropyridin-4-amine (200.0 mg, 1.23 mmol) in sulfolane (4090.0 μl) were added *p*-cresol (265.0 mg, 2.45 mmol) and K_2CO_3 (339.0 mg, 2.45 mmol). The reaction mixture was stirred at 160°C for 30 hours. The reaction mixture was extracted with EtOAc. The organic extract was washed with 1N-NaOH and brine, dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH_3CN : 0.1% formic acid in H_2O) and solidification with ACN/ether/Hex to obtain 2-chloro-6-(*p*-tolylloxy)pyridin-4-amine (160.0 mg, 56 %) as a light brown amorphous.

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ 7.17 (d, 2H, $J=8.2\text{Hz}$), 7.00 (d, 2H, $J=8.5\text{Hz}$), 6.30 (d, 1H, $J=1.7\text{Hz}$), 5.81 (d, 1H, $J=1.7\text{Hz}$), 4.22 (brs, 2H), 2.35 (s, 3H)

(b) Synthesis of *N*-(2-chloro-6-(*p*-tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide

The synthesis procedure of Example 1-b was repeated except for using 2-chloro-6-(*p*-tolylloxy)pyridin-4-amine (41.3 mg, 0.18 mmol) to obtain *N*-(2-chloro-6-(*p*-tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide (51.0 mg, 60 %) as a white amorphous.

LC/MS ESI (+): 529 (M+1)

$^1\text{H-NMR}$ (400MHz, $\text{DMSO-}d_6$): δ 10.89 (s, 1H), 8.29 (s, 1H), 8.05 (s, 1H), 7.64 (d, 1H, $J=1.4\text{Hz}$), 7.58 (s, 1H), 7.27 (d, 2H, $J=8.3\text{Hz}$), 7.21 (d, 1H, $J=1.4\text{Hz}$), 7.08 (d, 2H, $J=8.4\text{Hz}$), 4.81 (m, 1H), 4.44-4.51 (m, 1H), 4.29-4.34 (m, 1H), 3.16 (s, 3H), 2.59-2.67 (m, 1H), 2.32-2.34 (m, 4H)

Compounds from **Examples 16 to 42** were synthesized through the synthesis route of Example 15, and data of these compounds are listed as follows.

[Table 3]

Ex.	Compound	Analysis data
-----	----------	---------------

16	<i>N</i> -(2-chloro-6-(3-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 583 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.97 (s, 1H), 8.32 (s, 1H), 8.08 (s, 1H), 7.65-7.74 (m, 4H), 7.55-7.59 (m, 2H), 7.40 (d, 1H, <i>J</i> =1.2Hz), 4.81-4.84 (m, 1H), 4.49-4.53 (m, 1H), 4.31-4.34 (m, 1H), 3.17 (s, 3H), 2.60-2.68 (m, 1H), 2.35-2.36 (m, 1H)
17	<i>N</i> -(2-chloro-6-(4-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 583 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.98 (s, 1H), 8.32 (s, 1H), 8.08 (s, 1H), 7.85 (d, 2H, <i>J</i> =8.6Hz), 7.71 (s, 1H), 7.59 (s, 1H), 7.41-7.45 (m, 3H), 4.82-4.83 (m, 1H), 4.49-4.52 (m, 1H), 4.31-4.35 (m, 1H), 3.17 (s, 3H), 2.60-2.65 (m, 1H), 2.36-2.39 (m, 1H)
18	<i>N</i> -(2-chloro-6-(3,5-dichlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 583 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.98 (s, 1H), 8.32 (s, 1H), 8.08 (s, 1H), 7.70 (d, 2H, <i>J</i> =1.2Hz), 7.59 (s, 1H), 7.56 (t, 1H, <i>J</i> =2.0Hz), 7.44 (d, 2H, <i>J</i> =2.0Hz), 7.37 (s, 1H), 4.82-4.84 (m, 1H), 4.46-4.52 (m, 1H), 4.32-4.35 (m, 1H), 3.17 (s, 3H), 2.60-2.65 (m, 1H), 2.36-2.39 (m, 1H)
19	<i>N</i> -(2-chloro-6-(4-chloro-3-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 567 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.96 (s, 1H), 8.30 (s, 1H), 8.07 (s, 1H), 7.67-7.69 (m, 2H), 7.58 (s, 1H), 7.47 (d, 1H, <i>J</i> =10.3Hz), 7.35 (s, 1H), 7.15 (d, 1H, <i>J</i> =10.3Hz), 4.83-4.85 (m, 1H), 4.49-4.52 (m, 1H), 4.30-4.34 (m, 1H), 3.17 (s, 3H), 2.60-2.65 (m, 1H), 2.36-2.39 (m, 1H)
20	<i>N</i> -(2-chloro-6-(4-chloro-3-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): 10.92 (brs, 1H), 8.29 (s, 1H), 8.06 (s, 1H), 7.67 (s, 1H), 7.58 (s, 1H), 7.50 (d, 1H, <i>J</i> =8.7Hz), 7.25-7.26 (m, 2H), 7.09 (dd, 1H, <i>J</i> =8.6, 2.8Hz), 4.82 (m, 1H), 4.45-4.51 (m, 1H), 4.30-4.34 (m, 1H), 3.16 (s, 3H), 2.60-2.64 (m, 1H), 2.32-2.35 (m, 4H)
21	<i>N</i> -(2-chloro-6-(4-chloro-2-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): 10.92 (s, 1H), 8.30 (s, 1H), 8.06 (s, 1H), 7.64 (m, 1H), 7.58 (s, 1H), 7.47 (m, 1H), 7.35 (dd, 1H, <i>J</i> =8.6, 2.6Hz), 7.26 (m, 1H), 7.19 (d, 1H, <i>J</i> =8.6Hz), 4.81 (m, 1H), 4.45-4.51 (m, 1H), 4.30-4.34

		(m, 1H), 3.19 (s, 3H), 2.60-2.67 (m, 1H), 2.32-2.36 (m, 1H), 2.12 (s, 3H)
22	<i>N</i> -(2-chloro-6-(4-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 545 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.88 (s, 1H), 8.29 (s, 1H), 8.05 (s, 1H), 7.63 (d, 1H, <i>J</i> =1.2Hz), 7.58 (s, 1H), 7.19 (d, 1H, <i>J</i> =1.2Hz), 7.14 (d, 2H, <i>J</i> =9.0Hz), 7.01 (d, 2H, <i>J</i> =9.0Hz), 4.81 (m, 1H), 4.44-4.51 (m, 1H), 4.29-4.34 (m, 1H), 3.79 (s, 3H), 3.16 (s, 3H), 2.59-2.67 (m, 1H), 2.30-2.39 (m, 1H)
23	<i>N</i> -(2-chloro-6-(4-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 567 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.90 (brs, 1H), 8.24 (s, 1H), 8.00 (s, 1H), 7.62 (dd, 1H, <i>J</i> =10.4, 2.4Hz), 7.57 (s, 1H), 7.51 (s, 1H), 7.30-7.41 (m, 3H), 4.73-4.75 (m, 1H), 4.38-4.45 (m, 1H), 4.23-4.27 (m, 1H), 3.09 (s, 3H), 2.53-2.61 (m, 1H), 2.27-2.32 (m, 1H)
24	<i>N</i> -(2-chloro-6-(3,4-dichlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 585 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.88 (brs, 1H), 8.23 (s, 1H), 8.00 (s, 1H), 7.65 (d, 1H, <i>J</i> =8.8Hz), 7.60 (s, 1H), 7.57 (d, 1H, <i>J</i> =2.7Hz), 7.51 (s, 1H), 7.27 (s, 1H), 7.20 (dd, 1H, <i>J</i> =8.8, 2.7Hz), 4.73-4.75 (m, 1H), 4.38-4.45 (m, 1H), 4.23-4.27 (m, 1H), 3.09 (s, 3H), 2.53-2.60 (m, 1H), 2.27-2.32 (m, 1H)
25	<i>N</i> -(2-chloro-6-(3-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 549 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.87 (brs, 1H), 8.24 (s, 1H), 8.00 (s, 1H), 7.60 (s, 1H), 7.51 (s, 1H), 7.43 (t, 1H, <i>J</i> =8.1Hz), 7.28-7.31 (m, 2H), 7.26 (d, 1H, <i>J</i> =1.3Hz), 7.12-7.15 (m, 1H), 4.73-4.75 (m, 1H), 4.38-4.45 (m, 1H), 4.23-4.27 (m, 1H), 3.09 (s, 3H), 2.53-2.60 (m, 1H), 2.27-2.32 (m, 1H)
26	<i>N</i> -(2-chloro-6-(4-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 533 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.84 (brs, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.57 (s, 1H), 7.51 (s, 1H), 7.18-7.26 (m, 5H), 4.74-4.76 (m, 1H), 4.38-4.44 (m, 1H), 4.24-4.26 (m, 1H), 3.09 (s, 3H), 2.53-2.60 (m, 1H), 2.27-2.32 (m, 1H)
27	<i>N</i> -(2-chloro-6-(3-chloro-4-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -	LC/MS ESI (+): 567 (M+1) ¹ H-NMR(400MHz, DMSO- <i>d</i> ₆): δ 10.87 (brs, 1H), 8.23 (s, 1H), 8.00 (s, 1H), 7.59 (d, 1H,

	thieno[3,2-g]chromene-7-carboxamide	$J=0.8\text{Hz}$), 7.44-7.53 (m, 3H), 7.19-7.24 (m, 2H), 4.74-4.75 (m, 1H), 4.38-4.45 (m, 1H), 4.23-4.27 (m, 1H), 3.09 (s, 3H), 2.53-2.57 (m, 1H), 2.24-2.32 (m, 1H)
28	<i>N</i> -(2-chloro-6-(4-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2-g]chromene-7-carboxamide	LC/MS ESI (+): 599 (M+1) $^1\text{H-NMR}$ (400MHz, DMSO- d_6): δ 10.95 (brs, 1H), 8.28 (brs, 1H), 8.06 (s, 1H), 7.66 (s, 1H), 7.57 (s, 1H), 7.47 (d, 2H, $J=8.8\text{Hz}$), 7.33-7.36 (m, 3H), 4.81-4.82 (m, 1H), 4.45-4.52 (m, 1H), 4.29-4.34 (m, 1H); 3.16 (s, 3H), 2.60-2.64 (m, 1H), 2.31-2.39 (m, 1H)
29	<i>N</i> -(2-chloro-6-(3-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2-g]chromene-7-carboxamide	LC/MS ESI (+): 599 (M+1) $^1\text{H-NMR}$ (400MHz, DMSO- d_6): δ 10.96 (brs, 1H), 8.30 (s, 1H), 8.07 (s, 1H), 7.67 (d, 1H, $J=1.2\text{Hz}$), 7.58-7.62 (m, 2H), 7.37 (d, 1H, $J=0.8\text{Hz}$), 7.26-7.32 (m, 3H), 4.81-4.82 (m, 1H), 4.45-4.52 (m, 1H), 4.30-4.34 (m, 1H), 3.16 (s, 3H), 2.60-2.64 (m, 1H), 2.30-2.39 (m, 1H)
30	<i>N</i> -(2-chloro-6-(3-chloro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2-g]chromene-7-carboxamide	LC/MS ESI (+): 580 (M+1) $^1\text{H-NMR}$ (400MHz, DMSO- d_6): δ 10.87 (brs, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.61 (s, 1H), 7.50 (s, 1H), 7.22 (s, 1H), 6.89-6.90 (m, 1H), 6.85-6.86 (m, 1H), 6.74-6.75 (m, 1H), 4.74-4.75 (m, 1H), 4.38-4.43 (m, 1H), 4.23-4.27 (m, 1H), 3.75 (s, 3H), 3.09 (s, 3H), 2.53-2.57 (m, 1H), 2.29-2.32 (m, 1H)
31	<i>N</i> -(2-chloro-6-(3-chloro-5-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2-g]chromene-7-carboxamide	LC/MS ESI (+): 566 (M+1) $^1\text{H-NMR}$ (400MHz, DMSO- d_6): δ 10.90 (brs, 1H), 8.23 (s, 1H), 8.00 (s, 1H), 7.62 (s, 1H), 7.51 (s, 1H), 7.31-7.32 (m, 1H), 7.30 (s, 1H), 7.20 (s, 1H), 7.16-7.19 (m, 1H), 4.74-4.75 (m, 1H), 4.38-4.43 (m, 1H), 4.23-4.27 (m, 1H), 3.09 (s, 3H), 2.53-2.57 (m, 1H), 2.29-2.32 (m, 1H)
32	<i>N</i> -(2-chloro-6-(3-fluoro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2-g]chromene-7-carboxamide	LC/MS ESI (+): 563 (M+1) $^1\text{H-NMR}$ (400MHz, DMSO- d_6): δ 10.86 (brs, 1H), 8.22 (s, 1H), 7.99 (s, 1H), 7.61 (s, 1H), 7.50 (s, 1H), 7.22 (s, 1H), 6.64-6.72 (m, 2H), 6.61 (s, 1H), 4.74-4.76 (m, 1H), 4.38-4.44 (m, 1H), 4.24-4.26 (m, 1H), 3.72 (s, 3H), 3.09 (s, 3H), 2.53-2.60 (m, 1H), 2.27-2.32 (m, 1H)

33	<i>N</i> -(2-chloro-6-(<i>m</i> -tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 529 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.83 (brs, 1H), 8.22 (s, 1H), 7.98 (s, 1H), 7.59 (s, 1H), 7.50 (s, 1H), 7.28 (t, 1H, <i>J</i> =7.7Hz), 7.15 (s, 1H), 7.03 (d, 1H, <i>J</i> =7.6Hz), 6.95 (s, 1H), 6.91-6.93 (m, 1H), 4.74-4.76 (m, 1H), 4.38-4.44 (m, 1H), 4.24-4.26 (m, 1H), 3.09 (s, 3H), 2.53-2.60 (m, 1H), 2.27 (s, 3H), 2.27-2.32 (m, 1H)
34	<i>N</i> -(2-chloro-6-(3,4-difluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 551 (M+1) ¹ H-NMR(400MHz, DMSO- <i>d</i> ₆): δ 10.94 (brs, 1H), 8.29 (s, 1H), 8.06 (s, 1H), 7.65 (s, 1H), 7.47-7.58 (m, 3H), 7.31 (s, 1H), 7.10-7.14 (m, 1H), 4.81-4.82 (m, 1H), 4.45-4.51 (m, 1H), 4.30-4.34 (m, 1H), 3.16 (s, 3H), 2.60-2.64 (m, 1H), 2.30-2.39 (m, 1H)
35	<i>N</i> -(2-chloro-6-(5-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 567 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): 10.99 (brs, 1H), 8.32 (s, 1H), 8.08 (s, 1H), 7.65 (s, 1H), 7.62 (dd, 1H, <i>J</i> =6.9, 2.6Hz), 7.59 (s, 1H), 7.47-7.52 (m, 1H), 7.41-7.45 (m, 2H), 4.82 (m, 1H), 4.45-4.49 (m, 1H), 4.31-4.35 (m, 1H), 3.17 (s, 3H), 2.60-2.64 (m, 1H), 2.35-2.39 (m, 1H)
36	<i>N</i> -(2-chloro-6-(3-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 567 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): 11.00 (s, 1H), 8.32 (s, 1H), 8.09 (s, 1H), 7.66 (d, 1H, <i>J</i> =1.2Hz), 7.59 (s, 1H), 7.55 (td, 1H, <i>J</i> =8.4, 1.6Hz), 7.47 (s, 1H), 7.15 (td, 1H, <i>J</i> =9.2, 1.6Hz), 7.34 (td, 1H, <i>J</i> =8.4, 2.8Hz), 4.82-4.83 (m, 1H), 4.49-4.53 (m, 1H), 4.32-4.35 (m, 1H), 3.17 (s, 3H), 2.60-2.65 (m, 1H), 2.36-2.39 (m, 1H)
37	<i>N</i> -(2-chloro-6-(5-chloro-2-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 561 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.92 (s, 1H), 8.30 (s, 1H), 8.07 (s, 1H), 7.64 (d, 1H, <i>J</i> =1.2Hz), 7.58 (s, 1H), 7.40 (d, 1H, <i>J</i> =7.8Hz), 7.28 (m, 3H), 4.81 (m, 1H), 4.44-4.52 (m, 1H), 4.30-4.34 (m, 1H), 3.16 (s, 3H), 2.59-2.64 (m, 1H), 2.34-2.39 (m, 1H), 2.11 (s, 3H)
38	<i>N</i> -(2-chloro-6-(3-chloro-4-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.86 (brs, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.59 (s, 1H), 7.51 (s, 1H), 7.38 (d, 1H, <i>J</i> =8.3Hz), 7.29 (s, 1H), 7.20 (s, 1H), 7.05 (d, 1H, <i>J</i> =8.3Hz), 4.74-

		4.76 (m, 1H), 4.38-4.44 (m, 1H), 4.24-4.26 (m, 1H), 3.09 (s, 3H), 2.53-2.60 (m, 1H), 2.30 (s, 3H), 2.27-2.32 (m, 1H)
39	<i>N</i> -(2-chloro-6-(2-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 583 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.90 (brs, 1H), 8.25 (s, 1H), 8.00 (s, 1H), 7.78 (d, 1H, <i>J</i> =7.8Hz), 7.72 (t, 1H, <i>J</i> =7.8Hz), 7.59 (s, 1H), 7.51 (s, 1H), 7.38-7.44 (m, 2H), 7.33 (s, 1H), 4.74-4.76 (m, 1H), 4.38-4.44 (m, 1H), 4.24-4.26 (m, 1H), 3.09 (s, 3H), 2.53-2.57 (m, 1H), 2.27-2.32 (m, 1H)
40	<i>N</i> -(2-chloro-6-(2-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 599 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.91 (brs, 1H), 8.23 (s, 1H), 8.00 (s, 1H), 7.57 (s, 1H), 7.51 (s, 1H), 7.33-7.50 (m, 5H), 4.74-4.75 (m, 1H), 4.38-4.43 (m, 1H), 4.23-4.27 (m, 1H), 3.09 (s, 3H), 2.53-2.57 (m, 1H), 2.27-2.32 (m, 1H)
41	<i>N</i> -(2-chloro-6-(2-fluoro-3-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 547 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.94 (s, 1H), 8.30 (s, 1H), 8.07 (s, 1H), 7.64 (d, 1H, <i>J</i> =1.3Hz), 7.58 (s, 1H), 7.36 (d, 1H, <i>J</i> =1.1Hz), 7.14-7.24 (m, 3H), 4.81 (m, 1H), 4.44-4.52 (m, 1H), 4.30-4.34 (m, 1H), 3.16 (s, 3H), 2.59-2.64 (m, 1H), 2.33-2.39 (m, 1H), 2.29 (s, 3H)
42	<i>N</i> -(2-chloro-6-(4-chloro-2-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 579 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.81 (brs, 1H), 8.21 (s, 1H), 7.98 (s, 1H), 7.53 (s, 1H), 7.50 (s, 1H), 7.22 (d, 1H, <i>J</i> =2.3Hz), 7.17 (d, 1H, <i>J</i> =8.4Hz), 7.14 (s, 1H), 7.01 (dd, 1H, <i>J</i> =8.4, 2.3Hz), 4.73-4.74 (m, 1H), 4.38-4.44 (m, 1H), 4.23-4.27 (m, 1H), 3.69 (s, 3H), 3.09 (s, 3H), 2.52-2.57 (m, 1H), 2.20-2.27 (m, 1H)

Examples 43 and 44) Separation of (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide and (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide from rac-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide

The racemate of *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide (100.0 mg, 0.18 mmol) obtained in Example 8 was separated by preparative HPLC (Daicel Chiralpak IA, dichloromethane/ethanol=98/2, 10.0mL/min, 254nm, 35°C) into (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide (45.0 mg, 45%) and (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide (44.0 mg, 44%).

Example 43) (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide

LC/MS ESI (+): 549 (M+1).

¹H-NMR (400MHz, DMSO-*d*₆): 10.96 (s, 1H), 8.31 (s, 1H), 8.06 (s, 1H), 7.66 (s, 1H), 7.58 (s, 1H), 7.52 (d, 2H, *J*=8.80Hz), 7.31 (s, 1H), 7.27 (d, 2H, *J*=8.80Hz), 4.82 (m, 1H), 4.45-4.51 (m, 1H), 4.30-4.34 (m, 1H), 3.16 (s, 3H), 2.60-2.64 (m, 1H), 2.29-2.39 (m, 1H).

HPLC: Daicel Chiralpak IA, 0.46 cm I.D. x 15 cm L, dichloromethane/ethanol=98/2, 1.0mL/min, 254nm, 35°C, *t*_R= 3.08 min.

Example 44) (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide

LC/MS ESI (+): 549 (M+1).

¹H-NMR (400MHz, DMSO-*d*₆): 11.03 (s, 1H), 8.32 (s, 1H), 8.06 (s, 1H), 7.66 (s, 1H), 7.57 (s, 1H), 7.52 (d, 2H, *J*=8.79Hz), 7.31 (s, 1H), 7.26 (d, 2H, *J*=8.79Hz), 4.82 (m, 1H), 4.45-4.51 (m, 1H), 4.30-4.33 (m, 1H), 3.16 (s, 3H), 2.60-2.64 (m, 1H), 2.30-2.39 (m, 1H).

HPLC: Daicel Chiralpak IA, 0.46 cm I.D. x 15 cm L, dichloromethane/ethanol=98/2, 1.0mL/min, 254nm, 35°C, *t*_R= 3.95 min.

Compounds from **Examples 45 to 49** were synthesized through the synthesis route of Example 43 and 44, and data of these compounds are listed as follows.

[Table 4]

Ex.	Compound	Analysis data
45	(<i>S</i>)- <i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 567 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.97 (brs, 1H), 8.26 (s, 1H), 8.24 (s, 1H), 7.63 (s, 1H), 7.58 (s, 1H), 7.45 (d, 2H, <i>J</i> =8.7Hz), 7.22 (s, 1H), 7.19 (d, 2H, <i>J</i> =8.7Hz), 4.46-4.53 (m,

		1H), 4.32-4.36 (m, 1H), 3.24 (s, 3H), 2.87-2.94 (m, 1H), 2.61-2.71 (m, 1H)
46	(<i>R</i>)- <i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 567 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.91 (brs, 1H), 8.26 (s, 1H), 8.23 (s, 1H), 7.63 (s, 1H), 7.57 (s, 1H), 7.46 (d, 2H, <i>J</i> =8.7Hz), 7.21 (s, 1H), 7.19 (d, 2H, <i>J</i> =8.7Hz), 4.46-4.49 (m, 1H), 4.31-4.37 (m, 1H), 3.24 (s, 3H), 2.86-2.90 (m, 1H), 2.64-2.70 (m, 1H)
47	(<i>S</i>)- <i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.94 (brs, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 7.65 (s, 1H), 7.57 (s, 1H), 7.52 (d, 2H, <i>J</i> =8.5Hz), 7.30 (s, 1H), 7.25 (d, 2H, <i>J</i> =8.3Hz), 4.49-4.54 (m, 1H), 4.20-4.24 (m, 1H), 2.98 (s, 3H), 2.62 (m, 1H), 2.15-2.22 (m, 1H), 1.84 (s, 3H)
48	(<i>R</i>)- <i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 563 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.94 (brs, 1H), 8.29 (s, 1H), 8.25 (s, 1H), 7.65 (s, 1H), 7.57 (s, 1H), 7.52 (d, 2H, <i>J</i> =8.5Hz), 7.30 (s, 1H), 7.25 (d, 2H, <i>J</i> =8.3Hz), 4.49-4.54 (m, 1H), 4.20-4.24 (m, 1H), 2.98 (s, 3H), 2.62 (m, 1H), 2.15-2.22 (m, 1H), 1.84 (s, 3H)
49	(<i>S</i>)- <i>N</i> -(2-chloro-6-(3-chloro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 580 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.86 (brs, 1H), 8.23 (s, 1H), 7.99 (s, 1H), 7.62 (s, 1H), 7.51 (s, 1H), 7.22 (s, 1H), 6.89-6.90 (m, 1H), 6.85-6.86 (m, 1H), 6.74-6.76 (m, 1H), 4.74-4.75 (m, 1H), 4.39-4.44 (m, 1H), 4.23-4.27 (m, 1H), 3.73 (s, 3H), 3.09 (s, 3H), 2.52-2.57 (m, 1H), 2.28-2.32 (m, 1H)

Examples 50) Synthesis of *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxamide

5 *tert*-butyl 7-((2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)carbamoyl)-1-(methylsulfonyl)-2,3-dihydrothieno[2,3-*g*]quinoxaline-4(1*H*)-carboxylate (7.0 mg, 10.78 μmol) was dissolved in CH₂Cl₂ (108.0 μl), and TFA (300 μl, 3.89 mmol) was added at 20°C. The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain *N*-(2-chloro-6-(4-

10

chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-
g]quinoxaline-7-carboxamide (2.5 mg, 42 %) as white amorphous.

Examples 51) Synthesis of *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-8-oxo-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide

To a solution of *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide (20.0 mg, 0.04 mmol) in acetic anhydride (1.0 ml, 10.58 mmol) was added chromium oxide(VI) (11.0 mg, 0.11 mmol) at 0°C. The reaction mixture was stirred at 0°C for 2 hours. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-8-oxo-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide (5.0 mg, 24 %) as a white amorphous.

LC/MS ESI (+): 561 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 11.14 (s, 1H), 8.72 (s, 1H), 8.46 (s, 1H), 8.23 (s, 1H), 7.68 (d, 1H, *J*=1.2Hz), 7.52 (d, 2H, *J*=8.8Hz), 7.33 (d, 1H, *J*=1.2Hz), 7.26 (d, 2H, *J*=8.8Hz), 4.99 (m, 1H), 3.17 (s, 3H), 3.02-3.09 (m, 1H), 2.79-2.83 (m, 1H), 2.61-2.67 (m, 2H)

Examples 52) Synthesis of *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide

To a suspension of 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxylic acid (17.0 mg, 0.06 mmol) in CH₂Cl₂ (0.3 ml) were added (COCl)₂ (9.6 μl, 0.11 mmol) and DMF (0.4 μl, 5.66 μmol). The reaction mixture was stirred at 40°C for 1 hour, and concentrated under reduced pressure to obtain 4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carbonyl chloride. To the residue, 2-chloro-6-(4-chlorophenoxy)pyridin-4-amine (28.9 mg, 0.11 mmol) and 1,4-dioxane (0.3 ml) was added. The reaction mixture was stirred at 80°C overnight. The reaction mixture was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH₃CN : 0.1% formic acid in H₂O) to obtain *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(1*H*-pyrazol-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide (21.0 mg, 69 %) as a white solid.

LC/MS ESI (+): 537 (M+1)

¹H-NMR (400MHz, DMSO-*d*₆): δ 10.77 (brs, 1H), 8.08 (s, 1H), 7.74 (d, 1H, *J*=2.0Hz), 7.55 (s, 1H), 7.43-7.48 (m, 4H), 7.33 (s, 1H), 7.16-7.20 (m, 3H), 6.23-6.25 (m, 1H), 5.80 (t, 1H, *J*=6.2Hz), 4.27-4.3 (m, 2H), 2.31-2.43 (m, 2H)

Compounds from **Examples 53 to 55** were synthesized through the synthesis route

of Example 52, and data of these compounds are listed as follows.

[Table 5]

Ex.	Compound	Analysis data
53	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 554 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.93 (s, 1H), 8.23 (s, 1H), 7.66 (s, 1H), 7.59 (s, 1H), 7.48-7.53 (m, 3H), 7.24-7.29 (m, 3H), 5.43-5.47 (m, 1H), 4.29-4.42 (m, 2H), 3.24-3.29 (m, 1H), 2.95-3.00 (m, 1H), 2.35-2.44 (m, 2H), 2.11-2.22 (m, 1H), 1.90-2.03 (m, 3H)
54	<i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-cyano-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 496 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.89 (brs, 1H), 8.21 (s, 1H), 7.96 (s, 1H), 7.58 (s, 1H), 7.49 (s, 1H), 7.46 (d, 2H, <i>J</i> =8.8Hz), 7.23 (s, 1H), 7.19 (d, 2H, <i>J</i> =8.8Hz), 4.57-4.60 (m, 1H), 4.23-4.26 (m, 2H), 2.22-2.33 (m, 2H)
55	4-azido- <i>N</i> -(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-3,4-dihydro-2 <i>H</i> -thieno[3,2- <i>g</i>]chromene-7-carboxamide	LC/MS ESI (+): 512 (M+1) ¹ H-NMR (400MHz, DMSO- <i>d</i> ₆): δ 10.96 (brs, 1H), 8.31 (s, 1H), 8.04 (s, 1H), 7.65 (s, 1H), 7.56 (s, 1H), 7.52 (d, 2H, <i>J</i> =8.8Hz), 7.31 (s, 1H), 7.26 (d, 2H, 8.8Hz), 5.09 (t, 1H, <i>J</i> =3.9Hz), 4.35-4.40 (m, 1H), 4.16-4.23 (m, 1H), 2.23-2.25 (m, 1H), 1.98-2.05 (m, 1H)

5

Examples 56) Synthesis of *N*-(3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)phenyl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide

10 (a) Synthesis of 1-chloro-3-nitro-5-(prop-1-en-2-yl)benzene

To a suspension of 1-bromo-3-chloro-5-nitrobenzene (7.2 g, 30.59 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (5.1 g, 30.59 mmol) and Na₂CO₃ (9.7 g, 91.76 mmol) in DME (120.0 mL)/H₂O (30.0 mL) was added Pd(PPh₃)₄ (1.8 g, 1.53 mmol). The reaction mixture was refluxed overnight. Pd(PPh₃)₄ (0.7 g, 0.61 mmol) was
15 more added and stirred for 4hours. After cooling to room temperature, the reaction mixture was filtered through celite. The filtrate was concentrated and the residue was extracted with EtOAc. The organic extract was washed with brine, dried over anhydrous Na₂SO₄, filtered and concentrated. The residue was purified by NH-silica column chromatography (hexane only) to give 1-chloro-3-nitro-5-(prop-1-en-2-yl)benzene (6.3 g) as a crude yellow

oil.

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ 8.19 (t, 1H, $J=1.7\text{Hz}$), 8.11 (t, 1H, $J=1.8\text{Hz}$), 7.74 (t, 1H, $J=1.7\text{Hz}$), 5.30 (s, 1H), 2.19 (s, 3H)

5 (b) Synthesis of 1-(2-bromopropan-2-yl)-3-chloro-5-nitrobenzene

To a solution of 1-chloro-3-nitro-5-(prop-1-en-2-yl)benzene (6.3 g, 22.14 mmol) in Et_2O (100.0 mL) was added 33wt% HBr in ACN (38.8 mL, 221.38 mmol). The reaction mixture was stirred at room temperature for 2 days. Sat. NaHCO_3 aqueous solution was added under ice bath and the resulting mixture was extracted with Et_2O . The organic
10 extract was washed with sat. NaHCO_3 aqueous solution and brine, dried over anhydrous Na_2SO_4 , filtered and concentrated. The residue was purified by flash column chromatography (silica gel, $n\text{-Hex} : \text{EtOAc} = 19 : 1$) to obtain 1-(2-bromopropan-2-yl)-3-chloro-5-nitrobenzene (5.3 g, 62% in 2 steps) as an ivory solid.

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ 8.34 (t, 1H, $J=1.9\text{Hz}$), 8.13 (t, 1H, $J=1.9\text{Hz}$), 7.26
15 (t, 1H, $J=1.8\text{Hz}$), 2.21 (s, 6H)

(c) Synthesis of 1-chloro-3-(2-(4-chlorophenyl)propan-2-yl)-5-nitrobenzene

1-(2-Bromopropan-2-yl)-3-chloro-5-nitrobenzene (2.0 g, 7.18 mmol) and chlorobenzene (10.9 mL, 0.11 mol) were dissolved in 1,2-dichloroethane (70.0 mL), and
20 AlCl_3 (2.9 g, 21.54 mmol) was added. The reaction mixture was stirred at 0°C for 2 hours, H_2O was added, and extracted with CH_2Cl_2 . The organic extract was washed with brine, dried over anhydrous Na_2SO_4 and concentrated under reduced pressure. The residue was purified by reversed-phase column chromatography (C18-silica gel, 0.1% formic acid in CH_3CN : 0.1% formic acid in H_2O) to obtain 1-chloro-3-(2-(4-chlorophenyl)propan-2-yl)-5-nitrobenzene (1.95 g, 88%) as a yellow oil.

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ 8.06 (t, 1H, $J=1.8\text{Hz}$), 7.99 (t, 1H, $J=1.9\text{Hz}$), 7.47 (t, 1H, $J=1.7\text{Hz}$), 7.29 (d, 2H, $J=8.5\text{Hz}$), 7.12 (d, 2H, $J=8.5\text{Hz}$), 1.70 (s, 6H)

(d) Synthesis of 3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)aniline

1-chloro-3-(2-(4-chlorophenyl)propan-2-yl)-5-nitrobenzene (1.95 g, 6.28 mmol) was dissolved in $\text{MeOH/THF/H}_2\text{O}$ (65.0 mL, 10/2/1 v/v), and Zn (6.17 mg, 94.3 mmol) and NH_4Cl (1.68 g, 31.4 mmol) were added at room temperature. The reaction mixture was ultrasonicated at 40°C for 90 minutes, cooled to room temperature, filtered through Celite, and concentrated under reduced pressure. The residue was purified by flash column
35 chromatography (amine silica gel, $n\text{-Hex} : \text{EtOAc} = 9 : 1$) to obtain 3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)aniline (1.49 g, 85%) as a yellow oil.

LC/MS ESI (+): 280 (M+1)

$^1\text{H-NMR}$ (400MHz, CDCl_3): δ 7.22 (d, 2H, $J=8.7\text{Hz}$), 7.14 (d, 2H, $J=8.7\text{Hz}$), 6.60 (t, 1H, $J=1.7\text{Hz}$), 6.50 (t, 1H, $J=1.9\text{Hz}$), 6.32 (t, 1H, $J=1.9\text{Hz}$), 3.64 (s, 2H), 1.59 (s,
40 6H)

(e) Synthesis of *N*-(3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)phenyl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide

The synthesis procedure of Example 1-b was repeated except for using 3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)aniline (12.1 mg, 0.04 mmol) to obtain *N*-(3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)phenyl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide (12.8 mg, 77%) as a white solid.

LC/MS ESI (+): 575 (M+1)

¹H-NMR(400MHz, DMSO-*d*₆): δ 10.47 (s, 1H), 8.24 (s, 1H), 8.16 (s, 1H), 7.89 (s, 1H), 7.65 (s, 1H), 7.50 (t, 1H, *J*=1.6Hz), 7.39 (d, 2H, *J*=8.6Hz), 7.28 (d, 2H, *J*=8.6Hz), 7.03 (m, 1H), 4.37 (t, 2H, *J*=4.2Hz), 3.91 (t, 2H, *J*=4.4Hz), 3.19 (s, 3H), 1.66 (s, 6H).

Experimental Examples

Experiments were performed as shown below for the compounds prepared in Examples above.

Experimental Example 1) Experiment on the inhibition of STAT3 and STAT1 activities *via* reporter gene assay

1-1) Experiment on the inhibition of STAT3 activity

A human prostate cancer cell line (LNCaP stable cell line; plasmid pSTAT3-TA-luc), which contains a stably operating STAT3 promoter, was cultured in RPMI1640 medium (Cat No. 11875, Life Technologies) containing 10% fetal bovine serum (FBS) (Cat No. SH30396, Thermo Scientific) and 150 μg/mL G-418 solution (Cat No. 04 727 894 001, Roche). The reporter gene assay using LNCaP stable cell line was performed in RPMI1640 medium containing 3% DCC-FBS without G-418 solution. LNCaP stable cells were plated in two (2) white 96-well plates with 30,000 cells/50 μL in each well. The cells were cultured at 37°C, under 5% CO₂ for 24 hours, and then treated with the compounds listed in Examples which were diluted in various concentrations. Subsequently, IL-6 was added to each well with a final concentration of 10 ng/mL. Upon completion of the treatment with the compounds and IL-6, the cells were cultured at 37°C, under 5% CO₂ for 24 hours. The plates were observed under microscope and drug precipitation and particular findings were investigated and recorded.

The luciferase assay and the cell viability assay were performed respectively with one of the two plates. For the luciferase assay, the liquid media in the 96-well plate was removed, and then, 20 μL of passive cell lysis buffer was added to each well. After shaking the plate for 30 minutes, luciferase activities of each well were measured in a PHERAstarTM microplate reader (BMG LABTECH) using a luciferase assay system (Cat

No. E1501, Promega). For the cell viability assay, the 96-well plate was placed at room temperature for 30 minutes, added with 20 μ L/well of CellTiter-Glo solution (Cat No. G7573, Promega), and shaken for 10 minutes in order to measure cytotoxicity caused by the compounds listed in Examples with a PHERAstarTM microplate reader (BMG LABTECH). Wells without 0.1% DMSO and stimulation were used as a negative control and wells with 0.1% DMSO and stimulation were used as a positive control.

1-2) Experiment on the inhibition of STAT1 activity

A human osteosarcoma cell line (U2OS stable cell line; pGL4-STAT1-TA-luc), which contains a stably operating STAT1 promoter, was cultured in McCoy 5'A medium (Cat No. 16600, Life Technologies) containing 10% FBS (Cat No. SH30396, Thermo Scientific) and 1000 μ g /mL G418 solution (Cat No. 04 727 894 001, Roche). The reporter gene assay using U2OS stable cell line was performed in McCoy 5'A medium containing 10% FBS without G-418 solution. U2OS stable cells were plated in two (2) white 96-well plates with 25,000 cells/50 μ L in each well. The cells were cultured at 37°C, under 5% CO₂ for 24 hours, and then treated with the compounds listed in Examples which were diluted in various concentrations. Subsequently, IFN- γ was added to each well with a final concentration of 50 ng/mL. Upon completion of the treatment with the compounds and IFN- γ , the cells were cultured at 37°C, under 5% CO₂ for 8 hours. The plates were observed under microscope and drug precipitation and particular findings were investigated and recorded.

The luciferase assay and the cell viability assay were performed respectively with one of two plates. For the luciferase assay, the liquid media in the 96-well plate was removed, and then, 20 μ L of passive cell lysis buffer was added to each well. After shaking the plate for 30 minutes, luciferase activities of each well were measured in a PHERAstarTM microplate reader (BMG LABTECH) using a luciferase assay system (Cat No. E1501, Promega). For the cell viability assay, the 96-well plate was placed at room temperature for 30 minutes, added with 20 μ L/well of CellTiter-Glo solution (Cat No. G7573, Promega), and shaken for 10 minutes in order to measure cytotoxicity caused by the compounds listed in Examples with a PHERAstarTM microplate reader (BMG LABTECH). Wells without 0.1% DMSO and stimulation were used as a negative control and wells with 0.1% DMSO and stimulation were used as a positive control.

The results of evaluation on the inhibitory effect of the compounds listed in the Examples on the dimerization of STAT3 and STAT1 obtained *via* the STAT3 and STAT1 reporter gene assays are shown in Table 6 below.

[Table 6]

Ex.	IC ₅₀ (μ M) pSTAT3	IC ₅₀ (μ M) pSTAT1	Ex.	IC ₅₀ (μ M) pSTAT3	IC ₅₀ (μ M) pSTAT1
1	0.0026	>50	2	0.17	>50

3	0.01	>50	4	0.93	>50
5	0.76	>50	6	0.0030	>50
7	0.012	>50	8	0.024	>50
9	0.029	>50	10	0.0026	>50
11	0.0060	>50	12	0.0030	>50
13	0.0081	>50	14	0.029	>50
15	0.018	>50	16	0.0051	>50
17	0.0039	>50	18	0.015	>50
19	0.0084	>50	20	0.010	>50
21	0.011	>50	22	0.030	>50
23	0.0063	>50	24	0.0062	>50
25	0.011	>50	26	0.0073	>50
27	0.0078	>50	28	0.0051	>50
29	0.0059	>50	30	0.02	>50
31	0.008	>50	32	0.016	>50
33	0.0098	>50	34	0.0064	>50
35	0.010	>50	36	0.014	>50
37	0.0062	>50	38	0.0088	>50
39	0.014	>50	40	0.0087	>50
41	0.011	>50	42	0.023	>50
43	0.018	>50	44	1.5	>50
45	0.0039	>50	46	0.14	>50
47	0.0045	>50	48	0.15	>50
49	0.0066	>50	50	0.0082	>50
51	0.10	>50	52	0.10	>50
53	5.2	>50	54	0.18	16.6
55	0.039	17.9	56	0.0028	>50

As shown in Table 6, the compounds according to the present invention exhibited excellent inhibitory effects against the activity of STAT3 protein but showed almost no inhibitory effect against the activity of STAT1 protein.

5

Experimental Example 2) Cell growth inhibition assay

The inhibitory effects of the compounds of the present invention against the growth of cancer cells were evaluated as shown below. The cancer cell lines including stomach cancer cell line (NCI-N87) and breast cancer cell line (MDA-MB-468) were cultured under the protocol provided by each supplier. Each type of cells to be used in experiments was

10

sub-cultured in a 96-well plate by counting the exact number of cells using Tali™ Image-based Cytometer (Life Technologies). In a 96-well plate, NCI-N87 was employed with 5,000 cells/well; and MDA-MB-468 was employed with 10,000 cells/well. The cells were treated with the compounds listed in Examples which were diluted in various concentrations. Upon completion of the compounds treatment, NCI-N87 cells were cultured at 37°C under 5% CO₂ for 96 hours, and MDA-MB-468 cells were cultured at 37°C in air for 96 hours. Subsequently, the cells were observed under microscope and drug precipitation and particular findings were investigated and recorded. And then, the 96-well plate was placed at room temperature for 30 minutes, added with 20 µL/well of CellTiter-Glo solution (Cat No. G7573, Promega) and shaken for 10 minutes, followed by being subjected to the measurement using PHERAstar™ microplate reader (BMG LABTECH) according to the supplier's general luminometer protocol. Wells where only culture liquid added without cell plating were used as a negative control, whereas wells where culture liquid containing 0.1% DMSO instead of the compounds listed in Examples were used as a positive control.

The results of the inhibitory effects of the compounds prepared in Examples against the growth of cancer cells are shown in Tables 7 to 8 below.

[Table 7]

Ex.	IC ₅₀ (µM) NCI-N87	Ex.	IC ₅₀ (µM) NCI-N87	Ex.	IC ₅₀ (µM) NCI-N87	Ex.	IC ₅₀ (µM) NCI-N87
1	0.0083	2	1.2	3	0.045	4	4.1
5	0.72	6	0.0055	7	0.027	8	0.031
9	0.067	10	0.0060	11	0.01	12	0.0018
13	0.025	14	0.16	15	0.035	16	0.021
17	0.011	18	0.020	19	0.0061	20	0.0094
21	0.018	22	0.071	23	0.0056	24	0.0038
25	0.010	26	0.0072	27	0.0049	28	0.0056
29	0.0046	30	0.025	31	0.009	32	0.031
33	0.024	34	0.0092	37	0.0095	40	0.023
41	0.021	42	0.024	43	0.015	44	1.8
45	0.0056	46	0.56	47	0.0064	48	0.79
49	0.018	50	0.0091	51	0.20	52	0.40
53	4.4	54	0.32	55	1.2	56	0.019

[Table 8]


Ex.	IC ₅₀ (µM) MDA-MB-468	Ex.	IC ₅₀ (µM) MDA-MB-468	Ex.	IC ₅₀ (µM) MDA-MB-468	Ex.	IC ₅₀ (µM) MDA-MB-468
-----	-------------------------------------	-----	-------------------------------------	-----	-------------------------------------	-----	-------------------------------------

7	0.0065	8	0.0032	9	0.023	10	0.0019
11	0.0052	12	0.0028	13	0.0066	14	0.026
15	0.0089	16	0.0039	17	0.0023	18	0.0043
19	0.0025	20	0.0024	21	0.0051	22	0.017
23	0.0028	24	0.0024	25	0.0049	26	0.0046
27	0.0029	28	0.0020	29	0.0029	30	0.0085
31	0.0022	32	0.0089	33	0.0093	34	0.0023
37	0.0047	40	0.0086	41	0.012	42	0.0078
43	0.0029	44	0.086	45	0.0025	46	>0.10
47	0.0017	48	>0.10	49	0.0059	51	0.050
52	0.12	53	0.71	54	0.075	55	0.078


As shown in Tables 7 to 8, the compounds according to the present invention exhibited excellent inhibitory effects against the growth of various kinds of cancer cells.

WHAT IS CLAIMED IS:

1. A compound selected from the group consisting of a heterocyclic derivative represented by formula (I), and a pharmaceutically acceptable salt and a stereoisomer thereof:



wherein one of X_1 and X_2 is $-C(-R_x)(-R_x'')$ -, $-C(-R_x')(-R_x'')$ -, $-C(=O)$ -, $-N(R_x)$ - or $-N(-R_x')$ -, and the other is $-C(-R_x'')(-R_x'')$ -, $-N(-R_x'')$ - or $-O$ -;



X_s is $=O$ or $=NH$;

R_s is C_{1-6} alkyl, halo C_{1-6} alkyl, C_{1-6} alkoxy- C_{1-6} alkyl, C_{1-6} alkylcarbonyl- C_{1-6} alkyl, C_{2-7} alkenyl, amino, or amino C_{1-6} alkyl;

R_x' is halo C_{1-6} alkyl, C_{1-4} alkoxycarbonyl, cyano, nitro, azido, amino, or a 3-6 membered heterocyclyl unsubstituted or substituted with R_x'' ;

R_x'' is each independently hydrogen, halogen, nitro, amino, C_{1-6} alkyl, C_{1-6} alkoxy, halo C_{1-6} alkoxy, carbamoyl C_{1-6} alkyl, C_{1-6} alkylamino- C_{1-6} alkyl, or di C_{1-6} alkylamino- C_{1-6} alkyl;

one of Y and Z is $-S-$ or $-NH-$, and the other is $-CH=$ or $-N=$;

L_x is a saturated or unsaturated C_{1-4} hydrocarbon chain not containing or containing 1 to 3 heterogroups selected from the group consisting of $-O-$, $-NH-$, $-N=$, $-S-$, $-S(=O)-$ and $-S(=O)_2-$ in the chain, and unsubstituted or substituted with at least one R_x'' moiety;

A and B are each independently a monocyclic- or bicyclic-saturated or unsaturated C_{3-10} carbocycle or 5- to 12-membered heterocycle;

R_c is $=O$, $=NH$, $=N(-C_{1-6}alkyl)$, or $=N(-OH)$;

R_N is hydrogen or $C_{1-6}alkyl$;

L_B is $-[C(-R_L)(-R_L')]_m-$, $-[C(-R_L)(-R_L')]_n-O-$, $-O-$, $-NH-$, $-N(C_{1-6}alkyl)-$, $-S(=O)_2-$, $-C(=O)-$, or $-C(=CH_2)-$, wherein m is an integer of 0 to 3, n is an integer of 1 to 3, R_L and R_L' are each independently hydrogen, hydroxy, halogen or $C_{1-6}alkyl$, or R_L and R_L' are linked together to form $C_{1-6}alkylene$;

R_A is hydrogen, halogen, cyano, $C_{1-6}alkyl$, halo $C_{1-6}alkyl$, cyano $C_{1-6}alkyl$, $C_{1-6}alkylcarbonyl$, $C_{1-6}alkoxy$, halo $C_{1-6}alkoxy$, cyano $C_{1-6}alkoxy$, $C_{1-6}alkylamino$, di C_{1-6}

₆alkylamino, C₁₋₆alkylthio, C₁₋₆alkylaminocarbonyl, diC₁₋₆alkylaminocarbonyl, C₂₋₈alkynyl, C₁₋₆alkoxycarbonylamino-C₁₋₆alkoxy, aminoC₁₋₆alkoxy, or 3- to 6-membered heterocyclyl;

R_B is hydrogen, halogen, hydroxy, cyano, nitro, amino, oxo, aminosulfonyl, sulfonylamido, C₁₋₆alkylamino, C₁₋₆alkyl, haloC₁₋₆alkyl, cyanoC₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkoxy, cyanoC₁₋₆alkoxy, C₃₋₈cycloalkyloxy, C₂₋₈alkenyl, C₂₋₈alkenyloxy, C₂₋₈alkynyl, C₂₋₈alkynyloxy, C₁₋₆alkylamino-C₁₋₆alkoxy, diC₁₋₆alkylamino-C₁₋₆alkoxy, C₁₋₆alkoxy-carbonyl, carbamoyl, carbamoyl-C₁₋₆alkoxy, C₁₋₆alkylthio, C₁₋₆alkylsulfinyl, C₁₋₆alkylsulfonyl, 5- to 10-membered heterocyclyl, 5- to 10-membered heterocyclyl-C₁₋₆alkyl, 5- to 10-membered heterocyclyl-C₁₋₆alkoxy, or 5- to 10-membered heterocyclyl-oxy;

p is an integer of 0 to 4, and, when p is 2 or higher, R_A moieties are the same as or different from each other;

q is an integer of 0 to 4, and, when q is 2 or higher, R_B moieties are the same as or different from each other; and


each of said heterocycle and heterocyclyl moieties independently contains at least one heterogroup selected from the group consisting of -O-, -NH-, -N=, -S-, -S(=O)- and -S(=O)₂-.

2. The compound according to claim 1, wherein

one of Y and Z is -S- or -NH-, and the other is -CH=;

L_x is a saturated C₁₋₃ hydrocarbon chain not containing or containing at least one heteroatom selected from the group consisting of O, N and S in the chain, and unsubstituted or substituted with at least one substituent selected from the group consisting of halogen, C₁₋₆alkyl and C₁₋₆alkoxy;

one of X₁ and X₂ is -C(-R_x)(-R_{x'})-, -C(-R_{x'})(-R_{x''})-, -C(=O)-, -N(R_x)- or -N(-R_{x'})-, and the other is -C(-R_{x''})(-R_{x''})-, -N(-R_{x''})- or -O-;



X_s is =O or =NH;

R_s is C₁₋₆alkyl or haloC₁₋₆alkyl;

R_{x'} is haloC₁₋₆alkyl, cyano, nitro, amino, azido, or a 5- to 6-membered heterocyclyl containing at least one heteroatom selected from the group consisting of N, S and O and unsubstituted or substituted with oxo; and

R_{x''} is hydrogen, halogen, C₁₋₆alkyl, or C₁₋₄alkoxycarbonyl.

3. The compound according to claim 2, wherein

Y is -CH=;

Z is -S-;


R_C is =O;

R_N is hydrogen;

L_x is a saturated C₁₋₃ hydrocarbon chain not containing or containing oxygen atom in the chain, and unsubstituted or substituted with at least one substituent selected from the group consisting of halogen, C₁₋₆alkyl and C₁₋₆alkoxy;

X₁ is -C(-R_x)(-R_x''), -C(-R_x')(-R_x''), or -N(R_x)-;

X₂ is -C(-R_x'')(-R_x''), -C(=O)-, -N(-R_x''), or -O-;



Xs is =O or =NH;

R_x' is haloC₁₋₆alkyl, cyano, nitro, amino, azido, or a 5- to 6-membered heterocyclyl containing 1 to 2 heteroatoms selected from N and O and unsubstituted or substituted with oxo; and

R_x'' is hydrogen, halogen, C₁₋₆alkyl, or C₁₋₄alkoxycarbonyl.

4. The compound according to claim 3, wherein

A is benzene or a 5- to 10-membered heteroaryl containing 1 to 3 nitrogen atoms;

B is a monocyclic- or bicyclic-saturated or unsaturated C₆₋₁₀carbocycle or 5- to 10-membered heterocycle;

L_B is -[C(-R_L)(-R_L')] _m -, -O-, -NH- or -N(C₁₋₆alkyl)-, wherein m is 0 or 1, R_L and R_L' are each independently hydrogen, hydroxy, halogen or C₁₋₆alkyl, or R_L and R_L' are linked together to form C₂₋₅alkylene;

R_A is halogen, C₁₋₆alkoxycarbonylamino-C₁₋₆alkoxy, aminoC₁₋₆alkoxy, or 3- to 6-membered heterocyclyl;

R_B is halogen, C₁₋₆alkyl, C₁₋₆alkoxy, haloC₁₋₆alkyloxy, C₂₋₆alkenyloxy, C₃₋₁₀carbocyclyl-oxy, or 3- to 10-membered heterocyclyl-C₁₋₃alkoxy; and

each of said heteroaryl, heterocycle and heterocyclyl moieties independently contains 1 to 3 heteroatoms selected from the group consisting of O, N and S.

5. The compound according to claim 1, wherein

X₁ is -N(-R_x)-;

X₂ is -C(-R_x'')(-R_x'')- or -N(-R_x'')-;


Y is -CH=;

Z is -S-;

R_C is =O;

R_N is hydrogen;

Lx is ethylene substituted with one or two Rx" moieties,



Xs is =O;

Rs is methyl; and

Rx" is the same as defined in claim 1.

6. The compound according to claim 1, wherein

X₁ is -CH(-Rx)-;

X₂ is -N(-Rx")-;


Y is -CH=;

Z is -S-;

Rc is =O;

R_N is hydrogen;

Lx is ethylene;



Xs is =O;

Rs is methyl; and

Rx" is the same as defined in claim 1.

7. The compound according to claim 1, wherein

X₁ is -C(-Rx)(-Rx")-;

X₂ is -O-;


Y is -CH=;

Z is -S-;

Rc is =O;

R_N is hydrogen;

Lx is ethylene;




Xs is =O;

Rs is methyl; and

Rx" is the same as defined in claim 1.


8. The compound according to claim 1, wherein
 X_1 is $-C(-R_{x'})(-R_{x''})-$;
 X_2 is $-O-$;
 Y is $-CH=$;
 Z is $-S-$;
 R_c is $=O$;
 R_N is hydrogen;
 L_x is ethylene; and
 $R_{x'}$ and $R_{x''}$ are the same as defined in claim 1.

9. The compound according to claim 1, wherein
 X_1 is $-CH(-R_x)-$;
 X_2 is $-C(-R_{x''})(-R_{x''})-$ or $-C(=O)-$;
 Y is $-CH=$;
 Z is $-S-$;
 R_c is $=O$;
 R_N is hydrogen;
 L_x is ethylene;



- X_s is $=O$;
 R_s is methyl; and
 $R_{x''}$ is the same as defined in claim 1.

10. The compound according to claim 1, wherein
 X_1 is $-CH(-R_x)-$;
 X_2 is $-C(-R_{x''})(-R_{x''})-$;
 Y is $-CH=$;
 Z is $-S-$;
 R_c is $=O$;
 R_N is hydrogen;
 L_x is $-CH_2-O-$;



Rs is methyl; and

Rx" is the same as defined in claim 1.

11. The compound according to claim 1, wherein

X₁ is -C(-Rx)(-Rx")- or -N(Rx)-;

X₂ is -O-;

Y is -NH-;

Z is -CH=;

R_c is =O;

R_N is hydrogen;

Lx is propylene; and

Rx and Rx" are the same as defined in claim 1.

12. The compound according to claim 1, which is selected from the group consisting of:

1) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide;

2) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-3,3-dimethyl-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide;

3) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazepine-8-carboxamide;

4) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-8,8-dimethyl-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxamide;

5) *tert*-butyl 7-((2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)carbonyl)-1-(methylsulfonyl)-2,3-dihydrothieno[2,3-*g*]quinoxaline-4(1*H*)-carboxylate;

6) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,6,7,8-tetrahydrothieno[2,3-*g*]quinoline-2-carboxamide;

7) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxamide;

8) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

9) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-2,3,4,5-tetrahydrothieno[3',2':4,5]benzo[1,2-*b*]oxepine-8-carboxamide;

10) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide;

11) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

12) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-5,8-

dihydro-6*H*-thieno[3,2-*g*]isochromene-2-carboxamide;

13) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

14) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-8,8-difluoro-5-(methylsulfonyl)-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide;

15) *N*-(2-chloro-6-(*p*-tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

16) *N*-(2-chloro-6-(3-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

17) *N*-(2-chloro-6-(4-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

18) *N*-(2-chloro-6-(3,5-dichlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

19) *N*-(2-chloro-6-(4-chloro-3-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

20) *N*-(2-chloro-6-(4-chloro-3-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

21) *N*-(2-chloro-6-(4-chloro-2-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

22) *N*-(2-chloro-6-(4-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

23) *N*-(2-chloro-6-(4-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

24) *N*-(2-chloro-6-(3,4-dichlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

25) *N*-(2-chloro-6-(3-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

26) *N*-(2-chloro-6-(4-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

27) *N*-(2-chloro-6-(3-chloro-4-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

28) *N*-(2-chloro-6-(4-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

29) *N*-(2-chloro-6-(3-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

30) *N*-(2-chloro-6-(3-chloro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

31) *N*-(2-chloro-6-(3-chloro-5-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

32) *N*-(2-chloro-6-(3-fluoro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-

3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

33) *N*-(2-chloro-6-(*m*-tolylloxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

34) *N*-(2-chloro-6-(3,4-difluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

35) *N*-(2-chloro-6-(5-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

36) *N*-(2-chloro-6-(3-chloro-2-fluorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

37) *N*-(2-chloro-6-(5-chloro-2-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

38) *N*-(2-chloro-6-(3-chloro-4-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

39) *N*-(2-chloro-6-(2-(trifluoromethyl)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

40) *N*-(2-chloro-6-(2-(trifluoromethoxy)phenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

41) *N*-(2-chloro-6-(2-fluoro-3-methylphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

42) *N*-(2-chloro-6-(4-chloro-2-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

43) (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

44) (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

45) (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

46) (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-fluoro-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

47) (*S*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

48) (*R*)-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-methyl-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

49) (*S*)-*N*-(2-chloro-6-(3-chloro-5-methoxyphenoxy)pyridin-4-yl)-4-(methylsulfonyl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

50) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-1-(methylsulfonyl)-1,2,3,4-tetrahydrothieno[2,3-*g*]quinoxaline-7-carboxamide;

51) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-5-(methylsulfonyl)-8-oxo-5,6,7,8-tetrahydronaphtho[2,3-*b*]thiophene-2-carboxamide;

52) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(1*H*-pyrazol-1-yl)-3,4-

dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

53) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-(2-oxopyrrolidin-1-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

54) *N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-4-cyano-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide;

55) 4-azido-*N*-(2-chloro-6-(4-chlorophenoxy)pyridin-4-yl)-3,4-dihydro-2*H*-thieno[3,2-*g*]chromene-7-carboxamide; and

56) *N*-(3-chloro-5-(2-(4-chlorophenyl)propan-2-yl)phenyl)-1-(methylsulfonyl)-2,3-dihydro-1*H*-thieno[3',2':4,5]benzo[1,2-*b*][1,4]oxazine-7-carboxamide.

13. A pharmaceutical composition for preventing or treating diseases associated with the activation of STAT3 protein, comprising the compound as defined in any one of claims 1 to 12 as an active ingredient.

14. The pharmaceutical composition according to claim 13, wherein the diseases associated with the activation of STAT3 protein is selected from the group consisting of solid cancers, hematological or blood cancers, radio- or chemo-resistant cancers, metastatic cancers, inflammatory diseases, immunological diseases, diabetes, macular degeneration, human papillomavirus infection and tuberculosis.

15. The pharmaceutical composition according to claim 13, wherein the diseases associated with the activation of STAT3 protein are selected from the group consisting of breast cancer, lung cancer, stomach cancer, prostate cancer, uterine cancer, ovarian cancer, kidney cancer, pancreatic cancer, liver cancer, colon cancer, skin cancer, head and neck cancer, thyroid cancer, osteosarcoma, acute or chronic leukemia, multiple myeloma, B- or T-cell lymphoma, non-Hodgkin's lymphoma, auto-immune diseases comprising rheumatoid arthritis, psoriasis, hepatitis, inflammatory bowel disease, Crohn's disease, diabetes, macular degeneration, human papillomavirus infection, and tuberculosis.

16. A use of the compound as defined in any one of claims 1 to 12 for the manufacture of a medicament for preventing or treating diseases associated with the activation of STAT3 protein, wherein the diseases associated with the activation of STAT3 protein is selected from the group consisting of solid cancers, hematological or blood cancers, radio- or chemo- resistant cancers, metastatic cancers, inflammatory diseases, immunological diseases, diabetes, macular degeneration, human papillomavirus infection and tuberculosis.